<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004641.pub2" GROUP_ID="HTN" ID="164603102715302696" MERGED_FROM="" MODIFIED="2008-11-13 00:29:30 +0100" MODIFIED_BY="Ciprian Jauca" REVIEW_NO="A037" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2008-11-13 00:29:30 +0100" MODIFIED_BY="Ciprian Jauca">
<TITLE>Potassium supplementation for the management of primary hypertension in adults</TITLE>
<CONTACT MODIFIED="2008-11-13 00:29:30 +0100" MODIFIED_BY="Ciprian Jauca"><PERSON ID="13343" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Heather</FIRST_NAME><MIDDLE_INITIALS>O</MIDDLE_INITIALS><LAST_NAME>Dickinson</LAST_NAME><POSITION>Reader in Epidemiology</POSITION><EMAIL_1>heather.dickinson@newcastle.ac.uk</EMAIL_1><URL>www.staff.ncl.ac.uk/heather.dickinson</URL><ADDRESS><DEPARTMENT>Institute of Health and Society</DEPARTMENT><ORGANISATION>Newcastle University</ORGANISATION><ADDRESS_1>21 Claremont Place</ADDRESS_1><CITY>Newcastle upon Tyne</CITY><ZIP>NE2 4AA</ZIP><REGION>Tyne &amp; Wear</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 191 2223699</PHONE_1><PHONE_2>+44 191 2227045</PHONE_2><FAX_1>+44 191 2226043</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-13 00:29:30 +0100" MODIFIED_BY="Ciprian Jauca"><PERSON ID="13343" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Heather</FIRST_NAME><MIDDLE_INITIALS>O</MIDDLE_INITIALS><LAST_NAME>Dickinson</LAST_NAME><POSITION>Reader in Epidemiology</POSITION><EMAIL_1>heather.dickinson@newcastle.ac.uk</EMAIL_1><URL>www.staff.ncl.ac.uk/heather.dickinson</URL><ADDRESS><DEPARTMENT>Institute of Health and Society</DEPARTMENT><ORGANISATION>Newcastle University</ORGANISATION><ADDRESS_1>21 Claremont Place</ADDRESS_1><CITY>Newcastle upon Tyne</CITY><ZIP>NE2 4AA</ZIP><REGION>Tyne &amp; Wear</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 191 2223699</PHONE_1><PHONE_2>+44 191 2227045</PHONE_2><FAX_1>+44 191 2226043</FAX_1></ADDRESS></PERSON><PERSON ID="16CCDCCA82E26AA201B4268B9B5303F1" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Donald</FIRST_NAME><LAST_NAME>Nicolson</LAST_NAME><POSITION>Research Associate</POSITION><EMAIL_1>D.J.Nicolson@leeds.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>School of Healthcare</DEPARTMENT><ORGANISATION>University of Leeds</ORGANISATION><ADDRESS_1>Baines Wing</ADDRESS_1><CITY>Leeds</CITY><ZIP>LS2 9UT</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="18181" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Fiona</FIRST_NAME><LAST_NAME>Campbell</LAST_NAME><EMAIL_1>f.campbell@sheffield.ac.uk</EMAIL_1><MOBILE_PHONE>07788710296</MOBILE_PHONE><ADDRESS><DEPARTMENT>School of Health and Related Research</DEPARTMENT><ORGANISATION>University of Sheffield</ORGANISATION><ADDRESS_1>Regent Street</ADDRESS_1><CITY>Sheffield</CITY><ZIP>S1 4DA</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 114 2220767</PHONE_1></ADDRESS></PERSON><PERSON ID="14189" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Fiona</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Beyer</LAST_NAME><POSITION>Information Specialist</POSITION><EMAIL_1>fiona.beyer@ncl.ac.uk </EMAIL_1><ADDRESS><DEPARTMENT>Institute for Health and Society</DEPARTMENT><ORGANISATION>University of Newcastle</ORGANISATION><ADDRESS_1>19-21 Claremont Place</ADDRESS_1><CITY>Newcastle upon Tyne</CITY><ZIP>NE2 4AA</ZIP><REGION>Tyne &amp; Wear</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 191 222 3803</PHONE_1></ADDRESS></PERSON><PERSON ID="18996" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>James</FIRST_NAME><LAST_NAME>Mason</LAST_NAME><POSITION>Professor of Health Economics, Director of Research</POSITION><EMAIL_1>j.m.mason@durham.ac.uk </EMAIL_1><ADDRESS><DEPARTMENT>School of Medicine and Health</DEPARTMENT><ORGANISATION>Durham University, Queen's Campus</ORGANISATION><ADDRESS_1>Wolfson Research Institute</ADDRESS_1><ADDRESS_2>University Boulevard</ADDRESS_2><CITY>Stockton-on-Tees</CITY><ZIP>TS17 6BH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)191 334 0373</PHONE_1><FAX_1>+44 (0)191 334 0374</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-08-13 11:22:48 +0200" MODIFIED_BY="Ciprian Jauca">
<UP_TO_DATE>
<DATE DAY="1" MONTH="4" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="4" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="15" MONTH="4" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2008-11-13 00:29:30 +0100" MODIFIED_BY="Ciprian Jauca">

<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-13 00:29:30 +0100" MODIFIED_BY="Ciprian Jauca"><DATE DAY="12" MONTH="11" YEAR="2008"/><DESCRIPTION><P>Contact details updated</P></DESCRIPTION></WHATS_NEW_ENTRY></WHATS_NEW>
<HISTORY MODIFIED="2008-11-13 00:29:30 +0100" MODIFIED_BY="Ciprian Jauca"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-13 00:29:30 +0100" MODIFIED_BY="Ciprian Jauca">
<DATE DAY="13" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY></HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>National Institute for Clinical Excellence</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-08-13 12:19:33 +0300" MODIFIED_BY="Ciprian D Jauca">
<SUMMARY>
<TITLE>Oral potassium supplementation for high blood pressure in adults</TITLE>
<SUMMARY_BODY>
<P>This review examines whether taking potassium supplements can be recommended for treating adults with high blood pressure from no known cause. The results of the trials varied a lot: some trials found potassium lowered blood pressure much more than a dummy drug (placebo), while others found little difference between potassium and placebo. Overall no significant reduction in blood pressure from taking potassium supplements was found. </P>
<P>Most included trials were of poor quality, so their results may not be reliable. The trials were not long enough or large enough to measure whether potassium supplements reduce the risk of death, heart attack or stroke, which may be caused by high blood pressure. The studies reporting adverse effects did not find any serious side effects from taking potassium supplements.</P>
<P>This review does not confirm whether potassium supplements can lower high blood pressure and therefore does not recommend them for treating hypertension. More trials enrolling a large number of participants with long periods of follow-up are necessary to know whether or not potassium supplements can lower high blood pressure.<B>
<BR/>
</B>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-08-13 12:19:33 +0300" MODIFIED_BY="Ciprian D Jauca">
<ABS_BACKGROUND>
<P>Epidemiological evidence on the effects of potassium on blood pressure is inconsistent. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the effects of potassium supplementation on health outcomes and blood pressure in people with elevated blood pressure.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Library, MEDLINE, EMBASE, Science Citation Index, ISI Proceedings, ClinicalTrials.gov, Current Controlled Trials, CAB abstracts, and reference lists of systematic reviews, meta-analyses and randomised controlled trials (RCTs) included in the review.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Inclusion criteria were: 1) RCTs of a parallel or crossover design comparing oral potassium supplements with placebo, no treatment, or usual care; 2) treatment and follow-up &gt;=8 weeks; 3) participants over 18 years, with raised systolic blood pressure (SBP) &gt;=140 mmHg or diastolic blood pressure (DBP) &gt;=85 mmHg); 4) SBP and DBP reported at end of follow-up. We excluded trials where: participants were pregnant; received antihypertensive medication which changed during the study; or potassium supplementation was combined with other interventions.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two reviewers independently extracted data and assessed trial quality. Disagreements were resolved by discussion or a third reviewer. Random effects meta-analyses and sensitivity analyses were conducted.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-08-13 12:16:10 +0300" MODIFIED_BY="Ciprian D Jauca">
<P>Six RCT's<I> </I>(n=483), with 8-16 weeks follow-up, met our inclusion criteria.<I> </I>Meta-analysis of five trials (n=425) with adequate data indicated that potassium supplementation compared to control resulted in a large but statistically non-significant reductions in SBP (mean difference: -11.2, 95% CI: -25.2 to 2.7) and DBP (mean difference: -5.0, 95% CI: -12.5 to 2.4). The substantial heterogeneity between trials was not explained by potassium dose, quality of trials or baseline blood pressure.</P>
<P>Excluding one trial in an African population with very high baseline blood pressure resulted in smaller overall reductions in blood pressure (SBP mean difference: -3.9, 95% CI: -8.6 to 0.8; DBP mean difference: -1.5, 95% CI: -6.2 to 3.1). Further sensitivity analysis restricted to two high quality trials (n=138) also found non-significant reductions in blood pressure (SBP mean difference: -7.1, 95% CI: -19.9 to 5.7; DBP mean difference: -5.5, 95% CI: -14.5 to 3.5).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-08-13 12:19:33 +0300" MODIFIED_BY="Ciprian D Jauca">
<P>Potassium supplementation has no statistically significant effect on blood pressure. Due to small number of participants in the two high quality trials, the short duration of follow-up, and the unexplained heterogeneity between trials, the evidence about the effect of potassium supplementation on blood pressure is not conclusive. Further high quality RCTs of longer duration are required to clarify whether potassium supplementation can reduce blood pressure and improve health outcomes.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>High blood pressure, or hypertension is associated with a variety of structural changes in the blood vessels and heart. It is a risk factor for cardiovascular disease, stroke and renal disease and is one of the 10 leading risk factors influencing the global burden of disease. High blood pressure is estimated to lead to over 7 million deaths each year, about 13% of the total deaths worldwide (<LINK REF="REF-WHO-2002" TYPE="REFERENCE">WHO 2002</LINK>). Reducing blood pressure is associated with a significant reduction in cardiovascular and cerebrovascular morbidity and mortality (<LINK REF="REF-MacMahon-1990" TYPE="REFERENCE">MacMahon 1990</LINK>; <LINK REF="REF-PSC-2002" TYPE="REFERENCE">PSC 2002</LINK>). The most common form of hypertension - occurring in around 95% of all cases - is primary hypertension which is defined as high blood pressure with no identifiable cause (<LINK REF="REF-Brown-1997" TYPE="REFERENCE">Brown 1997</LINK>). Secondary hypertension is high blood pressure with an identifiable cause, e.g. renal disease or endocrine disturbances.</P>
<P>Epidemiological evidence about the effects of dietary potassium on blood pressure is inconsistent. Although several studies report an association between diets high in potassium and the prevention of hypertension, others do not (<LINK REF="REF-Burgess-1999" TYPE="REFERENCE">Burgess 1999</LINK>). Conflicting results may be due to the effect of potassium supplementation being influenced by dietary potassium intake, type of medication (e.g. diuretics), or level of blood pressure. Some studies have reported that the ratio of sodium to potassium in the urine is more closely correlated with blood pressure than either sodium or potassium alone (<LINK REF="REF-Kotchen-1998" TYPE="REFERENCE">Kotchen 1998</LINK>). A diet which is high in potassium appears to prevent retention of sodium and hence lower blood pressure (<LINK REF="REF-Buemi-2002" TYPE="REFERENCE">Buemi 2002</LINK>). Other physiological mechanisms, including the inhibition of proliferation of smooth vascular muscle cells and reduction in the vascular resistance, may underlie the antihypertensive effect of potassium (<LINK REF="REF-Buemi-2002" TYPE="REFERENCE">Buemi 2002</LINK>).</P>
<P>The Dietary Approaches to Stop Hypertension (DASH) trials reported that diets high in fruit and vegetables were effective in reducing blood pressure (<LINK REF="REF-Conlin-2000" TYPE="REFERENCE">Conlin 2000</LINK>). Although these diets were high in potassium, they were also high in other nutrients and low in fat and cholesterol, and so it is difficult to identify their effective components. </P>
<P>We found one systematic review (<LINK REF="REF-Burgess-1999" TYPE="REFERENCE">Burgess 1999</LINK>) and one meta-analysis (<LINK REF="REF-Whelton-1997" TYPE="REFERENCE">Whelton 1997</LINK>) summarising the findings of randomised controlled trials of oral potassium supplementation on blood pressure. The systematic review considered trials of potassium supplementation both for the treatment of hypertensive patients and for prevention of hypertension in normotensive participants. The authors concluded that potassium could not be recommended for either population (<LINK REF="REF-Burgess-1999" TYPE="REFERENCE">Burgess 1999</LINK>). The meta-analysis included 12 trials in normotensive people and 21 in hypertensive people, with a duration ranging from 4 days to 3 years (median 5 weeks) (<LINK REF="REF-Whelton-1997" TYPE="REFERENCE">Whelton 1997</LINK>). Overall, oral potassium supplementation was associated with a significant reduction in both systolic blood pressure (SBP) and diastolic blood pressure (DBP), for participants both with and without hypertension. The blood pressure lowering effect was greater in hypertensive than normotensive people and more pronounced in people eating a diet high in sodium chloride (common salt). The authors therefore recommended potassium supplementation for both prevention and treatment of hypertension, especially in people unable to reduce their intake of sodium.</P>
<P>Although most recent major guidelines for the treatment of hypertension recommend a diet rich in fruit and vegetables, none has recommended additional oral potassium supplementation (<LINK REF="REF-BHS-1999" TYPE="REFERENCE">BHS 1999</LINK>; <LINK REF="REF-Feldman-1999" TYPE="REFERENCE">Feldman 1999</LINK>; <LINK REF="REF-Euro-2003" TYPE="REFERENCE">Euro 2003</LINK>; <LINK REF="REF-ICSI-2003" TYPE="REFERENCE">ICSI 2003</LINK>; <LINK REF="REF-JNC-VII" TYPE="REFERENCE">JNC VII</LINK>; <LINK REF="REF-SAHS-2000" TYPE="REFERENCE">SAHS 2000</LINK>; <LINK REF="REF-NZGG-1997" TYPE="REFERENCE">NZGG 1997</LINK>; <LINK REF="REF-VHA-1999" TYPE="REFERENCE">VHA 1999</LINK>; <LINK REF="REF-WHO-1999" TYPE="REFERENCE">WHO 1999</LINK>).</P>
<P>The aim of this review was to summarise the evidence about the benefits and harms of dietary potassium supplementation for patients with primary hypertension, in order to inform decisions about recommendations for treatment. </P>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the effects of potassium supplementation for adults with primary hypertension.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>We included randomised controlled trials of a parallel or crossover design that had an intervention period of at least 8 weeks and allowed an intention to treat analysis. Crossover trials were restricted to designs with 2 interventions and 2 treatment periods.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Adults over 18 years of age, with raised blood pressure, defined as systolic blood pressure &#8805;140 mm Hg or diastolic blood pressure &#8805;85 mm Hg, without a known primary cause. The inclusion criterion for diastolic blood pressure is slightly lower than the standard (90 mmHg) for hypertension (JNC VII), in order to include individuals at the lower end of the spectrum of raised blood pressure.<BR/>We excluded:<BR/>
</P>
<UL>
<LI>studies of pregnant women, since hypertension during pregnancy is often due to syndromes such as preeclampsia, with a pathophysiology very different from that of other forms of hypertension (<LINK REF="REF-NIH-2000" TYPE="REFERENCE">NIH 2000</LINK>)</LI>
<LI>studies including patients on anti-hypertensive medication which varied during the course of the study, since the results of such studies are difficult to interpret.</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>We considered trials in which:<BR/>
</P>
<UL>
<LI>the intervention group received oral potassium supplementation, or dietary interventions which manipulated only potassium intake; </LI>
<LI>the control group received placebo, no treatment, or usual care.</LI>
</UL>
<P>
<BR/>We excluded trials which combined change in potassium intake with other interventions: for example, those that aimed to increase potassium while reducing sodium intake, and those that changed several aspects of diet.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>
<B>Primary outcome measures:<BR/>
</B>
</P>
<UL>
<LI>death from all causes</LI>
<LI>coronary heart disease events (fatal or non-fatal myocardial infarction, excluding heart failure and if possible angina)</LI>
<LI>cerebrovascular events (fatal or non-fatal strokes, excluding transient ischaemic attacks if possible).</LI>
<LI>SBP at end of follow-up</LI>
<LI>DBP at end of follow-up.</LI>
</UL>
<P>
<BR/>If the mean or standard deviation of final BP was not reported, the difference in BP between randomisation and the end of the study (change score) was used instead, if its standard deviation was available. </P>
<P>If BP was measured both supine and standing, supine measurements were preferred; if BP was measured both sitting and supine, sitting measurements were preferred. If blood pressure was measured in clinic and at home or in the workplace, clinic measurements were preferred. If only ambulatory blood pressure was measured, 12/7 was added to these measurements, as the British Hypertension Society recommends an upward correction of 12/7 mmHg to ambulatory values before comparing them with clinic values (<LINK REF="REF-Bruce-1999" TYPE="REFERENCE">Bruce 1999</LINK>).</P>
<P>
<B>Secondary outcome measures:</B>
<BR/>
</P>
<UL>
<LI>total withdrawal from treatment </LI>
<LI>withdrawals due to adverse effects</LI>
<LI>any adverse effects reported (eg. gastro-intestinal disturbances)</LI>
<LI>serum potassium levels at end of follow-up; although not specified in the initial protocol this was abstracted and post-hoc meta-analysis performed. Final values or change scores were abstracted as for blood pressure (see above).</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>We searched the following for RCTs:</P>
<UL>
<LI>Cochrane Library (2004 issue 1)</LI>
<LI>MEDLINE (2000 - 9th Jan 2004)</LI>
<LI>EMBASE (1999 - end 2003)</LI>
<LI>Science Citation Index (1982 - end 2003)</LI>
<LI>ISI Proceedings (1999 - end 2003)</LI>
<LI>ClinicalTrials.gov</LI>
<LI>Current Controlled Trials</LI>
<LI>CAB abstracts (up to end July 2005)</LI>
</UL>
<P>
<BR/>Since the Cochrane Library incorporates RCTs from MEDLINE and EMBASE, searches of these databases were restricted to recent years. </P>
<P>We also identified systematic reviews and meta-analyses from these databases and checked their reference lists, as well as those of randomised controlled trials included in the review.</P>
<P>We based the search on the following strategy (where terms in capitals are MeSH headings). This strategy was constructed and will be developed further within MEDLINE, and it will be adjusted accordingly for the other databases:</P>
<P>#1 HYPERTENSION/<BR/>#2 hypertens$.tw<BR/>#3 (blood ADJ pressure).tw<BR/>#4 #1 OR #2 OR #3<BR/>#5 DIETARY SUPPLEMENTS/<BR/>#6 POTASSIUM, DIETARY/<BR/>#7 potassium.tw AND (diet$ OR oral$ OR supplement$ OR intake$).tw<BR/>#8 #5 OR #6 OR #7<BR/>#9 Cochrane highly sensitive search strategy (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>)<BR/>#10 #4 AND #8 AND #9<BR/>#11 EXP PREGNANCY/<BR/>#12 (pre eclampsia or pre-eclampsia).tw<BR/>#13 (calcium antagonist or channel blocker).tw<BR/>#14 #11 OR #12 OR #13<BR/>#15 #10 NOT #14</P>
<P>We also carried out a general web search using the search engines Google, Zapmeta and Dogpile, and searched the web sites of the following organisations: Blood Pressure Association, British Hypertension Society, American Society of Hypertension, and Canadian Hypertension Society</P>
<P>There was no language restriction.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>All titles and abstracts retrieved by electronic searching were screened independently by two reviewers and those studies which clearly did not meet the inclusion criteria were excluded. Copies of the full text of potentially relevant references were obtained and their eligibility was assessed either by one reviewer, all of whose decisions were checked by a second reviewer, or independently by two reviewers. Differences between reviewers were resolved by discussion or by appeal to a third reviewer. </P>
<P>Methodological quality of included trials was assessed using the following criteria:</P>
<P>
<U>Blinding</U>
<BR/>We coded the blinding of participants, treatment providers and outcome assessors as:<BR/>
</P>
<UL>
<LI>yes</LI>
<LI>no</LI>
<LI>unclear.</LI>
</UL>
<P>
<BR/>
<U>Randomisation</U>
<BR/>We coded the randomisation of participants to intervention groups as:<BR/>
</P>
<UL>
<LI>adequate, e.g. a computer-generated random sequence or a table of random numbers</LI>
<LI>inadequate, e.g. date of birth, clinic id-number or surname</LI>
<LI>unclear, e.g. not reported.</LI>
</UL>
<P>
<BR/>
<U>Allocation concealment</U>
<BR/>We coded the concealment of the allocation sequence from treatment providers and participants as:<BR/>
</P>
<UL>
<LI>adequate, e.g. where the allocation sequence could not be foretold</LI>
<LI>inadequate, e.g. a method of allocation which allowed treatment providers to predict which arm of the trial the next participant was assigned to; this included use of sealed opaque envelopes;</LI>
<LI>unclear, e.g. not reported.</LI>
</UL>
<P>
<BR/>
<U>Loss to follow-up</U>
<BR/>We recorded the number of participants in each intervention arm whose blood pressure was not reported at the end of the study; we noted if loss to follow-up was not reported.</P>
<P>
<U>Carryover effects<BR/>
</U>For crossover trials, we noted whether carryover effects were assessed at the end of follow-up and, if so, whether any carryover effects reported.</P>
<P>Two reviewers independently abstracted endpoint data and data which might facilitate interpretation of any heterogeneity in the findings of trials: country in which the study was conducted, inclusion criteria, patient characteristics at baseline (age, gender, ethnicity, mean blood pressure, whether previously treated with antihypertensive drugs), trial quality and duration of follow-up using a pre-specified form. Differences were reconciled by discussion or by consultation with a third reviewer. Authors were contacted for missing endpoint data.</P>
<P>The findings of all included trials were aggregated in separate meta-analyses for (i) parallel and (ii) crossover designs; these were combined in the same meta-analysis if they did not show heterogeneity (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>; <LINK REF="REF-Curtin-2002" TYPE="REFERENCE">Curtin 2002</LINK>). For meta-analysis of parallel trials separately, final SBP and DBP (and standard deviations) in potassium and control arms were input to the mean difference facility of RevMan. For crossover trials separately, and for parallel and crossover trials combined, the generic inverse variance facility of RevMan was used. The mean difference (and standard deviation) between final blood pressure (or change score) for potassium and control interventions for both SBP and DBP was calculated. If standard deviations of final values were not available, change scores were used if their standard deviations were available. If no standard deviations were available, they were imputed. In particular, the standard deviation of the crossover treatment effect was imputed (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>), assuming the mean within-person correlation observed in other crossover trials which evaluated the effect on blood pressure of oral supplements of calcium, sodium and magnesium (<LINK REF="REF-Australian-1989" TYPE="REFERENCE">Australian 1989</LINK>; <LINK REF="REF-Galloe-1993" TYPE="REFERENCE">Galloe 1993</LINK>; <LINK REF="STD-Kawano-1998" TYPE="STUDY">Kawano 1998</LINK>; <LINK REF="REF-Kawano-1998-_x0028_ii_x0029_" TYPE="REFERENCE">Kawano 1998 (ii)</LINK>; <LINK REF="REF-McCarron-1985" TYPE="REFERENCE">McCarron 1985</LINK>). These mean differences were weighted according to the precision of each trial and combined in meta-analyses using a random effects model (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>), to estimate an overall pooled mean difference and its 95% confidence interval. Heterogeneity between trials was assessed using the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>; <LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). </P>
<P>Sub-group analyses were performed, grouping the trials into those in which (i) participants in the active treatment arm received higher (&gt;100 mmol/day) and lower (&lt;=100 mmol/day) doses of potassium, and (ii) participants' mean baseline blood pressure was higher (SBP&gt;145/95 mmHg) and lower (SBP&lt;=145/95 mmHg).</P>
<P>Sensitivity analyses were performed excluding trials which did not report (i) adequate concealment of allocation, (ii) blinding of participants, treatment providers and outcome assessors. Additionally, meta-analysis of parallel trials only was implicitly a sensitivity analysis excluding trials in which data were imputed, as the only trial for which data were imputed was the only included crossover trial. A post-hoc sensitivity analysis was performed, excluding one trial in an African population which had very different findings compared to other trials.</P>
<P>Further post-hoc analyses evaluated the effect of potassium supplementation on serum potassium levels using similar methods to above.</P>
<P>For parallel trials, we assessed the tolerability of the intervention by calculating the difference in the rate of withdrawal in treatment and control arms, and using a random effects model to calculate a pooled risk difference. Crossover trials are designed with the intention that all participants receive both the active and control interventions, and the treatment effect is estimated from the differences in response of the same participant to the different treatments. Hence participants who withdraw from either treatment cannot be included in the analysis and so the question of differential withdrawal between treatment arms does not arise. </P>
<P>If sufficient trials reported these outcomes, we intended to assess gastro-intestinal adverse effects by calculating the difference in the rate of these effects in treatment and control arms, and using a random effects model to calculate a pooled risk difference.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>The search strategy found 1282 potentially relevant references which we electronically screened (see Additional Figures: <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). We excluded 1034 references and retrieved 48 for more detailed evaluation. We excluded 42 references (after the full text of the paper was obtained) on the basis of follow-up of less than eight weeks (18 trials), normotensive participants (11 trials), antihypertensive medication varied during the trial (four trials), intervention consisted of multiple supplements (two trials), survey study design (two trials), follow-up of less than eight weeks and normotensive participants (one trial), participants not randomly allocated to the sequence of treatment (one trial), observational study (one trial), control group on drugs (one trial), trial of multiple interventions (one trial), and combined increased potassium with decreased sodium intake (one trial) - see table <B>Characteristics of Excluded Studies</B>.<I> </I>The six remaining RCTs met our inclusion criteria. <I> </I>One of these RCT's was reported only in an abstract and, although it met our inclusion criteria, it did not report the final SBP, the standard deviation of the change in SBP between baseline and end of follow-up, or the numbers in the treatment and control groups (<LINK REF="STD-Cushman-1988" TYPE="STUDY">Cushman 1988</LINK>). Hence we excluded this trial from the meta-analysis and from the detailed description of trials below. </P>
<P>The five RCT's included in the meta-analysis enrolled 425 participants and are described in the detail in the table <B>Characteristics of Included Studies</B>. Three trials were of parallel design (<LINK REF="STD-Obel-1989" TYPE="STUDY">Obel 1989</LINK>; <LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>; <LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>). One trial evaluated low sodium and high potassium diets, using a factorial design (<LINK REF="STD-Chalmers-1986" TYPE="STUDY">Chalmers 1986</LINK>); the effect of potassium was estimated, assuming no interaction between low sodium and high potassium diets by comparing effects among participants assigned and not assigned to the high potassium diet. One trial was of crossover design (<LINK REF="STD-Overlack-1991" TYPE="STUDY">Overlack 1991</LINK>). No trials were designed to assess mortality or cardiovascular endpoints and none reported whether participants experienced any of these events.</P>
<P>The number of participants in each trial ranged from 12 to 212. The median duration of follow-up was 12 weeks, (range: 8 weeks to 16 weeks). Overall 75%<B>
<I> </I>
</B>of the participants were male and the mean age was 50 years (range: 36-52<B>
<I> </I>
</B>years). Only two trials reported ethnicity and in these 61% of the participants were white (<LINK REF="STD-Obel-1989" TYPE="STUDY">Obel 1989</LINK>; <LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>). Trials were conducted in the USA (<LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>), Australia (<LINK REF="STD-Chalmers-1986" TYPE="STUDY">Chalmers 1986</LINK>), Kenya (<LINK REF="STD-Obel-1989" TYPE="STUDY">Obel 1989</LINK>), Germany (<LINK REF="STD-Overlack-1991" TYPE="STUDY">Overlack 1991</LINK>) and Italy (<LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>). Entry criteria were poorly reported and varied between trials. The entry criterion for SBP was reported in only two trials and was &gt;160 mm Hg in both (<LINK REF="STD-Obel-1989" TYPE="STUDY">Obel 1989</LINK>; <LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>). The entry criterion for DBP was reported in all trials: it was &gt;95 mmHg in the trial of <LINK REF="STD-Overlack-1991" TYPE="STUDY">Overlack 1991</LINK> and &gt;90 mmHg in all other trials. Most trials specified a maximum DBP of either 100 mmHg (<LINK REF="STD-Chalmers-1986" TYPE="STUDY">Chalmers 1986</LINK>), 105 mmHg (<LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>) or 110 mmHg (<LINK REF="STD-Obel-1989" TYPE="STUDY">Obel 1989</LINK>; <LINK REF="STD-Overlack-1991" TYPE="STUDY">Overlack 1991</LINK>) and one trial left the maximum open (<LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>). Overall mean blood pressure at baseline was 151/95 mmHg (SBP range: 145-174 mmHg; DBP range: 92-100 mmHg). </P>
<P>Little information was reported about the normal diet of participants. Two of the five included trials reported that serum potassium concentrations were normal in the populations studied (<LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>
<I>; </I>
<LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>
<I>)</I>; one reported that all participants had normal dietary intakes of sodium (<LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>)<I>. </I>
</P>
<P>The trials enrolled participants who were either treatment naive (<LINK REF="STD-Obel-1989" TYPE="STUDY">Obel 1989</LINK>), or currently untreated (<LINK REF="STD-Chalmers-1986" TYPE="STUDY">Chalmers 1986</LINK>; <LINK REF="STD-Overlack-1991" TYPE="STUDY">Overlack 1991</LINK>; <LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>; <LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>); one trial (<LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>) reported that participants were not receiving any medication which could affect potassium metabolism. </P>
<P>Trials measured BP in clinic while the patient was either seated (<LINK REF="STD-Chalmers-1986" TYPE="STUDY">Chalmers 1986</LINK>; <LINK REF="STD-Overlack-1991" TYPE="STUDY">Overlack 1991</LINK>; <LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>) or supine (<LINK REF="STD-Obel-1989" TYPE="STUDY">Obel 1989</LINK>; <LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>) and most trials took the average of two (<LINK REF="STD-Chalmers-1986" TYPE="STUDY">Chalmers 1986</LINK>; <LINK REF="STD-Obel-1989" TYPE="STUDY">Obel 1989</LINK>) or three (<LINK REF="STD-Overlack-1991" TYPE="STUDY">Overlack 1991</LINK>; <LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>) readings. Four trials reported the final value of blood pressure (<LINK REF="STD-Obel-1989" TYPE="STUDY">Obel 1989</LINK>; <LINK REF="STD-Overlack-1991" TYPE="STUDY">Overlack 1991</LINK>; <LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>; <LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>), but one reported only change scores (<LINK REF="STD-Chalmers-1986" TYPE="STUDY">Chalmers 1986</LINK>). The crossover trial of <LINK REF="STD-Overlack-1991" TYPE="STUDY">Overlack 1991</LINK> did not report the standard deviation of the treatment effect and this was imputed.</P>
<P>The intervention was provided as a simple oral potassium supplement in four trials (<LINK REF="STD-Obel-1989" TYPE="STUDY">Obel 1989</LINK>; <LINK REF="STD-Overlack-1991" TYPE="STUDY">Overlack 1991</LINK>; <LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>; <LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>); these trials gave a placebo to the control group. The dose of potassium varied between 48 and 120 mmol/day. (For potassium, 1g is 25.64 mmol).<B>
<I> </I>
</B>Three trials reported how many tablets per day were taken (<LINK REF="STD-Obel-1989" TYPE="STUDY">Obel 1989</LINK>; <LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>; <LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>), (range: six to 15). One trial (<LINK REF="STD-Chalmers-1986" TYPE="STUDY">Chalmers 1986</LINK>) encouraged individuals to increase their dietary intake of potassium and asked all participants in the control group to follow their usual diet.</P>
<P>Two trials reported adverse effects by treatment arm (<LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>; <LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>). Three of the five parallel trials reported the number of withdrawals from treatment by treatment arm (<LINK REF="STD-Chalmers-1986" TYPE="STUDY">Chalmers 1986</LINK>; <LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>; <LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>). The crossover trial of <LINK REF="STD-Overlack-1991" TYPE="STUDY">Overlack 1991</LINK> reported no withdrawals.</P>
<P>Serum potassium at the end of the trial was reported in both treatment arms in only two trials (<LINK REF="STD-Overlack-1991" TYPE="STUDY">Overlack 1991</LINK>; <LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>), although another trial reported that levels were similar in treatment and control groups (<LINK REF="STD-Obel-1989" TYPE="STUDY">Obel 1989</LINK>). In the trial of <LINK REF="STD-Overlack-1991" TYPE="STUDY">Overlack 1991</LINK>, the standard error of the crossover treatment effect was estimated from the reported p-value.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>While all trials claimed to be randomised, the method of randomisation was confirmed to be adequate in only one trial (<LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>). Concealment of allocation was confirmed to be adequate in two trials (<LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>; <LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>). One trial blinded both participants and treatment providers (<LINK REF="STD-Obel-1989" TYPE="STUDY">Obel 1989</LINK>); two trials blinded participants, treatment providers and outcome assessors (<LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>; <LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>); one trial blinded only outcome assessors (<LINK REF="STD-Overlack-1991" TYPE="STUDY">Overlack 1991</LINK>); and one trial was unclear in reporting whether participants, treatment providers or outcome assessors were blinded (<LINK REF="STD-Chalmers-1986" TYPE="STUDY">Chalmers 1986</LINK>). The crossover trial did not report on carryover effects (<LINK REF="STD-Overlack-1991" TYPE="STUDY">Overlack 1991</LINK>). Loss to follow-up, reported in all trials, was 4% and 6% in treatment and control groups respectively. <B>
<I>
<BR/>
</I>
</B>
</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>
<B>
<BR/>
</B>No trials reported deaths or cardiovascular events. Only two trials reported adverse effects, one of these reporting no adverse effects. Hence we meta-analysed only blood pressure, overall withdrawals from treatment and serum potassium levels. The trial which was excluded from meta-analysis (<LINK REF="STD-Cushman-1988" TYPE="STUDY">Cushman 1988</LINK>) reported no significant reduction in blood pressure among participants receiving potassium supplementation compared to the control group.</P>
<P>
<B>Primary meta-analyses</B>
<BR/>Three trials found a statistically significant reduction in SBP and DBP among participants receiving potassium supplementation compared to the control group (<LINK REF="STD-Chalmers-1986" TYPE="STUDY">Chalmers 1986</LINK>; <LINK REF="STD-Obel-1989" TYPE="STUDY">Obel 1989</LINK>; <LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>). Meta-analysis of the four parallel trials found that, overall, participants receiving potassium supplementation had a large but statistically non-significant reduction in both SBP (mean difference: -14.5 mmHg, 95% CI: -31.2 to 2.2) and DBP (mean difference: -7.5 mmHg, 95% CI: -16.1 to 1.1) compared to control - see comparison 1. There was considerable heterogeneity between trials (I<SUP>2</SUP> = 98%) for both SBP and DBP, largely because the trials of <LINK REF="STD-Obel-1989" TYPE="STUDY">Obel 1989</LINK> and <LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK> reported much larger reductions in blood pressure (39/17 mmHg and 14.0/10.5 mmHg respectively) than other trials among participants taking potassium supplements compared to those taking placebo. </P>
<P>Adding the crossover trial of <LINK REF="STD-Overlack-1991" TYPE="STUDY">Overlack 1991</LINK>, with imputed standard deviations of the treatment effects for SBP and DBP of 11.8 and 1.7 respectively, made little difference to the estimated treatment effect, which remained non-significant for both SBP (mean difference: -11.2 mmHg, 95% CI: -25.2 to 2.7) and DBP (mean difference: -5.0 mmHg, 95% CI: -12.5 to 2.4) - see comparison 2. The results remained very heterogeneous: (I<SUP>2</SUP> = 98% and 99% for SBP and DBP respectively). Sensitivity analysis, varying the within-person correlation and hence the imputed standard deviation of the treatment effect in the <LINK REF="STD-Overlack-1991" TYPE="STUDY">Overlack 1991</LINK> trial, made little difference to the overall estimated treatment effect (<LINK REF="REF-Dickinson-2003" TYPE="REFERENCE">Dickinson 2003</LINK>). </P>
<P>Subgroup analysis showed little difference between the effect of potassium in trials with lower (&lt;=145/95 mmHg) and higher baseline blood pressure (&gt;145/95 mmHg) - see comparison 3. The two trials administering lower (&lt;=100 mmol/day) doses of potassium (<LINK REF="STD-Obel-1989" TYPE="STUDY">Obel 1989</LINK>; <LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>) showed greater reductions in blood pressure than the three trials administering higher (<B>
<I>&gt;</I>
</B>100 mmol/day) doses (<LINK REF="STD-Chalmers-1986" TYPE="STUDY">Chalmers 1986</LINK>; <LINK REF="STD-Overlack-1991" TYPE="STUDY">Overlack 1991</LINK>; <LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>) and for DBP this difference was significant - see comparison 4.</P>
<P>
<B>Sensitivity analysis without Obel trial</B>
<BR/>The trial of <LINK REF="STD-Obel-1989" TYPE="STUDY">Obel 1989</LINK> enrolled treatment naive Kenyan participants who had an unusually high baseline BP (mean = 174/100 mmHg) and reported an effect of treatment much larger than that found in the other studies (mean difference in SBP: -39.0, 95% CI: -43.9 to 34.1; mean difference in DBP: -17.0, 95% CI: -19.3 to 14.7). We therefore conducted a post-hoc sensitivity analysis excluding this trial. Meta-analysis of the remaining four trials resulted in smaller and also non-significant reductions in blood pressure (SBP mean difference: -3.9, 95% CI: -8.6 to 0.8; DBP mean difference -1.5, 95% CI: -6.2 to 3.1) - see comparison 5. Heterogeneity was reduced but remained substantial (I<SUP>2</SUP> = 73% and 95% for SBP and DBP respectively).</P>
<P>
<B>Sensitivity analysis of high quality trials<BR/>
</B>Only two trials (<LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>; <LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>) reported adequate concealment of allocation, and these trials also blinded participants, treatment providers and outcome assessors. A sensitivity analysis restricted to these high quality trials found the overall reduction in blood pressure among participants taking potassium supplementation remained non-significant for both SBP (mean difference: -7.1, 95% CI: -19.9 to 5.7) and DBP (mean difference: -5.5, 95% CI: -14.5 to 3.5) - see comparison 6. There was considerable heterogeneity between the trials (I<SUP>2</SUP> = 87% for both SBP and DBP), largely because <LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK> reported a large and statistically significant reduction in blood pressure among participants receiving potassium, whereas <LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK> reported a small, non-significant reduction.</P>
<P>
<B>Total withdrawal from treatment</B>
<I>
<BR/>
</I>The rate of withdrawal from treatment for all causes was reported in three parallel trials (<LINK REF="STD-Chalmers-1986" TYPE="STUDY">Chalmers 1986</LINK>
<I>; </I>
<LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>
<I>; </I>
<LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>): withdrawal rates were 5% in the treatment group and 9% in the control group. Meta-analysis showed no significant difference in rate of withdrawal between the treatment groups (risk difference = -0.03, 95%CI: -0.07 to 0.02 - see comparison 1, outcome 3). </P>
<P>The crossover trial of <LINK REF="STD-Overlack-1991" TYPE="STUDY">Overlack 1991</LINK> reported no withdrawals. <I>
<BR/>
</I>
<BR/>
<B>Adverse effects</B>
<BR/>One trial reported mild side effects in both treatment and control groups (<LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>), with more stomach pains and flatulence in the potassium-treated group. One trial reported no adverse effects in either group (<LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>).</P>
<P>
<B>Withdrawals due to adverse effects</B>
<BR/>Only one trial (<LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>) reported withdrawal due to adverse effects separately from overall withdrawal. This study reported significantly more withdrawal due to adverse effects in the control group than in the treatment group (risk difference = -0.11, 95%CI: -0.20 to -0.01).</P>
<P>
<B>Serum potassium<BR/>
</B>Meta-analysis of the two trials reporting final serum potassium levels (<LINK REF="STD-Overlack-1991" TYPE="STUDY">Overlack 1991</LINK>; <LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>) showed that, overall, participants receiving potassium supplementation had higher serum potassium levels at the end of the trials than those in the control groups (mean difference: 0.20 mmol/l, 95% CI: 0.02 to 0.38) - see comparison 2, outcome 3. There was no heterogeneity between the trials: I<SUP>2</SUP> = 0%. </P>
<P>
<B>Funnel plot analysis</B>
<BR/>We considered the potential for small study effects by visually examining funnel plots of estimated treatment effects for SBP and DBP and found little evidence of publication bias (see Additional Figures: <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>
<B>Effect of intervention</B>
<BR/>The trials were not designed to assess the effects of potassium supplementation on the risk of death, heart attack or stroke and no trials reported these outcomes. Therefore we relied on the surrogate endpoint of blood pressure. Our meta-analysis of five randomised controlled trials enrolling 425 participants, with between eight and 16 weeks follow-up, did not find any robust evidence that potassium supplementation reduced blood pressure, compared to control. Overall, potassium supplementation was associated with a large but statistically non-significant reduction in SBP, and a smaller non-significant reduction in DBP. As the majority of trials were not of good quality (see below), these results must be interpreted with caution. We found little evidence of publication bias. </P>
<P>The trials did not give consistent results, with some reporting a large decrease in blood pressure among people receiving potassium supplementation and others reporting an increase. Subgroup analysis showed that this could not be ascribed to differences in baseline blood pressure. Although further subgroup analysis suggested that trials administering a lower dose of potassium achieved a greater reduction in blood pressure than other trials, this must be interpreted with caution: it is probably a chance finding consequent to multiple subgroup analysis of a small number of trials (<LINK REF="REF-Cochrane-handbook" TYPE="REFERENCE">Cochrane handbook</LINK>). Although the standard deviation of the treatment effect was imputed in the crossover trial of <LINK REF="STD-Overlack-1991" TYPE="STUDY">Overlack 1991</LINK> inclusion of this trial was not the cause of the heterogeneity, which was apparent in meta-analysis of parallel trials with no imputed data. Substantial heterogeneity remained after exclusion of one trial which reported an extreme result: the <LINK REF="STD-Obel-1989" TYPE="STUDY">Obel 1989</LINK> trial reported an average reduction of 39/17 mm Hg among participants receiving potassium supplementation compared to control. The large magnitude of this reduction may be due to the participants being treatment naive and/or having a very high baseline blood pressure (174/100 mm Hg). The participants' ethnic background may also be a factor. A previous meta-analysis of potassium supplementation found a greater blood pressure reduction in black compared to white participants (<LINK REF="REF-Whelton-1999" TYPE="REFERENCE">Whelton 1999</LINK>), which may be due to ethnic differences in diet or physiology (<LINK REF="REF-He-2003" TYPE="REFERENCE">He 2003</LINK>). Nevertheless, a reduction in blood pressure of the magnitude found by <LINK REF="STD-Obel-1989" TYPE="STUDY">Obel 1989</LINK> requires confirmation from further independent research. Substantial heterogeneity remained when the meta-analysis was further restricted to the two good quality trials (<LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>; <LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>), although these trials were conducted in populations with similar baseline blood pressure and proportion of men. The ethnic mix was probably also similar: although ethnicity was not reported in the trial of <LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>, most participants were probably white as the trial was conducted in Italy; the trial of <LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK> reported that 86% of participants were white. The heterogeneity between the findings of the included trials is unlikely to be due to differences in methods of measuring BP, as all trials measured BP in clinic. Furthermore, within each trial, the same method of measurement applied to both potassium and control groups and so should have little effect on the difference between the final values in these groups. The heterogeneity could be due to unreported differences in the populations studied, such as dietary potassium or sodium intake.</P>
<P>The number of withdrawals from treatment for any reason was reported in 3 trials enrolling 365 participants; overall the rate of withdrawal was similar in treatment and control groups. Only one trial (<LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>) reported the reasons for withdrawals and in this trial only 3 (2%) participants dropped out because of adverse effects; one trial (<LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>) reported no withdrawals; and one trial (<LINK REF="STD-Chalmers-1986" TYPE="STUDY">Chalmers 1986</LINK>) did not report the reasons for withdrawals. The only evidence of adverse effects due to potassium supplementation came from the <LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK> trial which reported a higher rate of gastro-intestinal side-effects in the treatment than the control group.<BR/>
<I> </I>
<B>
<I>
<BR/>
</I>
</B>
<B>Previous findings<BR/>
</B>The meta-analysis by <LINK REF="REF-Whelton-1997" TYPE="REFERENCE">Whelton 1997</LINK> included 20 trials enrolling 1,512 participants with hypertension, with between 4 days and 24 weeks length of follow-up. After excluding the trial of <LINK REF="STD-Obel-1989" TYPE="STUDY">Obel 1989</LINK> which reported a very large reduction in blood pressure among participants receiving potassium, this meta-analysis found a statistically significant reduction in SBP (mean difference = -4.4 mm Hg, 95% CI: -6.6 to -2.2) and DBP (mean difference = -2.5 mm Hg, CI: -4.9 to -0.1) favouring potassium supplementation. Since the Whelton review did not specify a minimum length of follow-up it included trials with a very short follow-up period (four days). We would argue that four days follow-up is too short and that our criteria of a minimum of 8 weeks is more reasonable to draw meaningful conclusions about compliance and the long-term effects of treatment for a chronic condition. </P>
<P>The systematic review by <LINK REF="REF-Burgess-1999" TYPE="REFERENCE">Burgess 1999</LINK> did not include a meta-analysis.</P>
<P>
<B>Quality of trials</B>
<BR/>Of the five trials included in the meta-analyses, only two blinded the participants, treatment providers and outcome assessors (<LINK REF="STD-Siani-1987" TYPE="STUDY">Siani 1987</LINK>; <LINK REF="STD-Svetkey-1987" TYPE="STUDY">Svetkey 1987</LINK>). Both trials adequately concealed treatment allocation. However these trials reported inconsistent results which, when combined, did not clearly demonstrate that potassium was effective in reducing blood pressure.</P>
<P>In the remaining three studies (<LINK REF="STD-Chalmers-1986" TYPE="STUDY">Chalmers 1986</LINK>; <LINK REF="STD-Obel-1989" TYPE="STUDY">Obel 1989</LINK>; <LINK REF="STD-Overlack-1991" TYPE="STUDY">Overlack 1991</LINK>), concealment of allocation was unclearly reported. Trials with inadequate or unclear concealment of allocation are more likely than adequately concealed trials to show beneficial effects of treatment (<LINK REF="REF-Egger-2003" TYPE="REFERENCE">Egger 2003</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). Furthermore, only one of these four trials reported blinding of both the participant and treatment provider (<LINK REF="STD-Obel-1989" TYPE="STUDY">Obel 1989</LINK>). Trials in which the participant and treatment provider are not blinded are also more likely to report beneficial effects of the intervention (<LINK REF="REF-Egger-2003" TYPE="REFERENCE">Egger 2003</LINK>; <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). Evidence from these poorer quality trials should not be given as much weight as evidence from those of higher quality. </P>
<P>
<B>Conclusions</B>
<BR/>Neither the primary meta-analysis nor the sensitivity analyses showed a statistically significant reduction in blood pressure among participants receiving potassium supplementation. The most striking aspect of the meta-analysis was the unexplained heterogeneity between the findings of trials: even the two good quality trials gave inconsistent results. The heterogeneity could be due to unreported differences in the populations studied, such as dietary potassium or sodium intake.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Evidence from trials of at least 8 weeks in duration does not show that oral potassium supplementation reduces high blood pressure. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Further placebo-controlled RCTs are warranted to clarify whether potassium supplementation can reduce blood pressure compared to control in people with mild to moderate elevations in blood pressure and, if so, whether the effect is limited to particular groups of people. These trials should be of high quality with adequate concealment of allocation and blinding of participants, treatment providers and outcome assessors. They should enrol a large number of participants and have long enough follow-up to allow detection of any meaningful long-term effects of potassium supplementation. The treatment effect should be reported in relation to the ethnic group of participants and their baseline dietary intake of potassium and sodium. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We thank Sarah Hull for help with data abstraction and Sylvia Hudson and Beth Anderson for secretarial support.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None. The funding source was not in a position to benefit financially from the results of the review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>JM designed the study; HOD and FC wrote the protocol; FRB and HOD performed the searches and managed the references; DJN, FC and HOD sifted the references; DJN, HOD, FC and JM performed the data abstraction; HOD, JM and DJN performed the statistical analyses; HOD and DJN wrote the review</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Chalmers-1986" NAME="Chalmers 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers J, Morgan T, Doyle A, Dickson B, Hopper J, Mathews J, Matthews J, Moulds R, Myers J, Nowson C, Scoggins B, Stebbing M</AU>
<TI>Australian National Health and Medical Research Council dietary salt study in mild hypertension</TI>
<SO>Journal of Hypertension</SO>
<YR>1986</YR>
<VL>4</VL>
<NO>Suppl 6</NO>
<PG>S629-S637</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cushman-1988" NAME="Cushman 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cushman WC, Langford HG</AU>
<TI>Randomized controlled trial of potassium chloride versus placebo in mildly hypertensive blacks and whites</TI>
<SO>Circulation</SO>
<YR>1988</YR>
<VL>78</VL>
<NO>4 Suppl II</NO>
<PG>II-370</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Obel-1989" NAME="Obel 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Obel AO</AU>
<TI>Placebo-controlled trial of potassium supplements in black patients with mild essential hypertension</TI>
<SO>Journal of Cardiovascular Pharmacology</SO>
<YR>1989</YR>
<VL>14</VL>
<NO>2</NO>
<PG>294-296</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Overlack-1991" NAME="Overlack 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Overlack A, Conrad H, Stumpe KO</AU>
<TI>The influence of oral potassium citrate/ bicarbonate on blood pressure in essential hypertension during unrestricted salt intake</TI>
<SO>Klinische Wochenschrift</SO>
<YR>1991</YR>
<VL>69</VL>
<NO>Suppl 25</NO>
<PG>79-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siani-1987" NAME="Siani 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siani A, Strazzullo P, Russo L, Guglielmi S, Iacoviello L, Ferrara LA</AU>
<TI>Controlled trial of long term oral potassium supplements in patients with mild hypertension</TI>
<SO>BMJ</SO>
<YR>1987</YR>
<VL>294</VL>
<NO>6585</NO>
<PG>1453-1456</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svetkey-1987" NAME="Svetkey 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svetkey LP, Yarger WE, Feussner JR, DeLong E, Klotman PE</AU>
<TI>Double-blind placebo-controlled trial of potassium chloride in the treatment of mild hypertension</TI>
<SO>Hypertension</SO>
<YR>1987</YR>
<VL>9</VL>
<NO>5</NO>
<PG>444-450</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Appel-1995" NAME="Appel 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Appel LJ, Hebert PR, Cohen JD, Obarzanek E, Yamamoto M, Buring J</AU>
<TI>Baseline characteristics of participants in phase II of the Trials of Hypertension Prevention (TOHP II)</TI>
<SO>Annals of Epidemiology</SO>
<YR>1995</YR>
<VL>5</VL>
<NO>2</NO>
<PG>149-155</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barden-1986" NAME="Barden 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barden AE, Vandongen R, Beilin LJ, Margetts B, Rogers P</AU>
<TI>Potassium supplementation does not lower blood pressure in normotensive women</TI>
<SO>Journal of Hypertension</SO>
<YR>1986</YR>
<VL>4</VL>
<NO>3</NO>
<PG>339-343</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barden-1991" NAME="Barden 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barden A, Beilin LJ, Vandongen R, Puddey IB</AU>
<TI>A double-blind placebo-controlled trial of the effects of short-term potassium supplementation on blood pressure and atrial natriuretic peptide in normotensive women</TI>
<SO>American Journal of Hypertension</SO>
<YR>1991</YR>
<VL>4</VL>
<NO>3 Pt 1</NO>
<PG>206-213</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bompiani-1988" NAME="Bompiani 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bompiani GD, Ceralosa G, Morici ML, Condorelli M, Trimarco B, De Luca N, et al.</AU>
<TI>Effects of moderate low sodium/high potassium diet on essential hypertension: results of a comparative study</TI>
<SO>International Journal of Clinical Pharmacology, Therapy and Toxicology</SO>
<YR>1988</YR>
<VL>26</VL>
<NO>3</NO>
<PG>129-132</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brancati-1996" NAME="Brancati 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brancati FL, Appel LJ, Seidler AJ, Whelton PK</AU>
<TI>Effect of potassium supplementation on blood pressure in African Americans on a low-potassium diet: a randomized double-blind placebo-controlled trial</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1996</YR>
<VL>156</VL>
<NO>1</NO>
<PG>61-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bulpitt-1985" NAME="Bulpitt 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bulpitt CJ</AU>
<TI>Potassium supplementation fails to lower blood pressure in hypertensive patients receiving a potassium losing diuretic</TI>
<SO>Annals of Clinical Research</SO>
<YR>1985</YR>
<VL>17</VL>
<NO>4</NO>
<PG>126-130</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fotherby-1992" NAME="Fotherby 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fotherby MD, Potter JF</AU>
<TI>Potassium supplementation reduces clinic and ambulatory blood pressure in elderly hypertensive patients</TI>
<SO>Journal of Hypertension</SO>
<YR>1992</YR>
<VL>10</VL>
<NO>11</NO>
<PG>1403-1408</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geleijnse-1994" NAME="Geleijnse 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geleijnse JM, Witteman J, Bak AA, den Breeijen JH, Grobbee DE</AU>
<TI>Reduction in blood pressure with a low sodium high potassium high magnesium salt in older subjects with mild to moderate hypertension</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6952</NO>
<PG>436-440</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geleijnse-1995" NAME="Geleijnse 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geleijnse JM, Witteman JCM, Bak AAA, Den BJH, Grobbee DE</AU>
<TI>Reducing blood pressure by use of a low sodium high potassium, high magnesium mineral salt in older persons with mild to moderate hypertension</TI>
<SO>Nederlands Tijdschrift voor Geneeskunde</SO>
<YR>1995</YR>
<VL>139</VL>
<NO>10</NO>
<PG>512-518</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grimm-1988" NAME="Grimm 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grimm RH, Kofron PM, Neaton JD, Svendson KH, Elmer PJ, Holland L, Witte LJ, Clearman DR, Prineas RJ</AU>
<TI>Effect of potassium supplementation combined with dietary sodium reduction on blood pressure in men taking anti-hypertensive medication</TI>
<SO>Journal of Hypertension</SO>
<YR>1988</YR>
<VL>6</VL>
<NO>Suppl 4</NO>
<PG>S591-S593</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grimm-1990" NAME="Grimm 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grimm RH, Neaton JD, Elmer PJ, Svendsen KH, Levin J, Segal M, Holland L, Witte LJ, Clearman DR, Kofron P, LaBounty RK, Crow R, Prineas R</AU>
<TI>The influence of oral potassium chloride on blood pressure in hypertensive men on a low-sodium diet</TI>
<SO>North of England Journal of Medicine</SO>
<YR>1990</YR>
<VL>322</VL>
<NO>9</NO>
<PG>569-574</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grobbee-1987" NAME="Grobbee 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grobbee DE, Hofman A, Roelandt JT, Boomsma F, Schalekamp MA, Valkenburg HA</AU>
<TI>Sodium restriction and potassium supplementation in young people with mildly elevated blood pressure</TI>
<SO>Journal of Hypertension</SO>
<YR>1987</YR>
<VL>5</VL>
<NO>1</NO>
<PG>115-119</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gruchow-1988" NAME="Gruchow 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gruchow HW, Sobocinski KA, Barboriak JJ</AU>
<TI>Calcium intake and the relationship of dietary sodium and potassium to blood pressure</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1988</YR>
<VL>48</VL>
<NO>6</NO>
<PG>1463-1470</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hebert-1995" NAME="Hebert 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hebert PR, Bolt RJ, Borhani NO, Cook NR, Cohen JD, Cutler JA, Hollis JF, Kuller LH, Lasser NL, Oberman A, Miller ST, Morris CA, Whelton PK, Hennekens C</AU>
<TI>Design of a multicenter trial to evaluate long-term life-style intervention in adults with high-normal blood pressure levels: Trials of Hypertension Prevention (phase II)</TI>
<SO>Annals of Epidemiology</SO>
<YR>1995</YR>
<VL>5</VL>
<NO>2</NO>
<PG>130-139</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hollis-1995" NAME="Hollis 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hollis JF, Satterfield S, Smith F, Fouad M, Allender PS, Borhani N, Charleston J, Hirlinger M, King N, Schultz R, Sousoulas BG</AU>
<TI>Recruitment for Phase II of the Trials of Hypertension Prevention: effective strategies and predictors of randomization.</TI>
<SO>Annals of Epidemiology</SO>
<YR>1995</YR>
<VL>5</VL>
<NO>2</NO>
<PG>140-148</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iimura-1981" NAME="Iimura 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iimura O, Kijima T, Kikuchi K, Miyama A, Ando T, Nakao T, Takigama Y</AU>
<TI>Studies on the hypotensive effect of high potassium intake in patients with essential hypertension</TI>
<SO>Clinical Science</SO>
<YR>1981</YR>
<VL>61</VL>
<NO>Suppl 7</NO>
<PG>77s-80s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Intersalt-1988" NAME="Intersalt 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Intersalt Cooperative Research Group</AU>
<TI>Intersalt: an international study of electrolyte excretion and blood pressure results for 24-hour urinary sodium and potassium excretion</TI>
<SO>BMJ</SO>
<YR>1988</YR>
<VL>297</VL>
<NO>6644</NO>
<PG>319-328</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jula-1990" NAME="Jula 1990" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jula A, Ronnemaa T, Rastas M, Kravetti R-L, Maki J</AU>
<TI>Long-term nopharmacological treatment for mild to moderate hypertension</TI>
<SO>Journal of Internal Medicine</SO>
<YR>1990</YR>
<VL>227</VL>
<NO>6</NO>
<PG>413-421</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaplan-1985" NAME="Kaplan 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaplan NM, Carnegie A, Raskin P, Heller JA, Simmons M</AU>
<TI>Potassium supplementation in hypertensive patients with diuretic-induced hypokalemia</TI>
<SO>North of England Journal of Medicine</SO>
<YR>1985</YR>
<VL>312</VL>
<NO>12</NO>
<PG>746-749</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kawamura-1993" NAME="Kawamura 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kawamura M, Akasaka T, Kasatsuki T, Nakajima J, Onodera S, Fujiwara T, Hiramori K</AU>
<TI>Blood pressure is reduced by short-time calorie restriction in overweight hypertensive women with a constant intake of sodium and potassium</TI>
<SO>Journal of Hypertension</SO>
<YR>1993</YR>
<VL>11</VL>
<NO>Suppl 5</NO>
<PG>S320-S321</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kawano-1998" NAME="Kawano 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kawano Y, Minami J, Takishita S, Omae T</AU>
<TI>Effects of potassium supplementation on office, home and 24-hour blood pressure in patients with essential hypertension</TI>
<SO>American Journal of Hypertension</SO>
<YR>1998</YR>
<VL>11</VL>
<NO>10</NO>
<PG>1141-1146</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khaw-1982" NAME="Khaw 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khaw KT, Thom S</AU>
<TI>Randomized double-blind cross-over trial of potassium on blood-pressure in normal subjects</TI>
<SO>Lancet</SO>
<YR>1982</YR>
<VL>2</VL>
<NO>2308</NO>
<PG>1127-1128</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kromhout-1985" NAME="Kromhout 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kromhout D, Bosschieter EB, Coulander CD</AU>
<TI>Potassium calcium alcohol intake and blood pressure: the Zutphen Study</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1985</YR>
<VL>41</VL>
<NO>6</NO>
<PG>1299-1304</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Langford-1991" NAME="Langford 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Langford HG, Davis BR, Blaufox D, Oberman A, Wassertheil-Smoller S, Hawkins M, Zimbaldi N</AU>
<TI>Effect of drug and diet treatment of mild hypertension on diastolic blood pressure</TI>
<SO>Hypertension</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>2</NO>
<PG>210-217</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MacGregor-1982" NAME="MacGregor 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MacGregor GA, Smith SJ, Markandu ND, Banks RA, Sagnella GA</AU>
<TI>Moderate potassium supplementation in essential hypertension</TI>
<SO>Lancet</SO>
<YR>1982</YR>
<VL>2</VL>
<NO>8298</NO>
<PG>567-570</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matlou-1986" NAME="Matlou 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matlou SM, Isles CG, Higgs A, Milne FJ, Murray GD, Schultz E, Starke IF</AU>
<TI>Potassium supplementation in blacks with mild to moderate essential hypertension</TI>
<SO>Journal of Hypertension</SO>
<YR>1986</YR>
<VL>4</VL>
<NO>1</NO>
<PG>61-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MRC-1987" NAME="MRC 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Medical Research Council Working Party</AU>
<TI>Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trial of treatment of mild hypertension</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1987</YR>
<VL>27</VL>
<NO>4</NO>
<PG>271-277</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Omvik-1995" NAME="Omvik 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Omvik P, Myking OL</AU>
<TI>Unchanged central hemodynamics after six months of moderate sodium restriction with or without potassium supplementation in essential hypertension</TI>
<SO>Blood Pressure</SO>
<YR>1995</YR>
<VL>4</VL>
<NO>1</NO>
<PG>32-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Overlack-1983" NAME="Overlack 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Overlack A, Muller HM, Kolloch R, Ollig A, Moch B, Kleinmann R</AU>
<TI>Long-term antihypertensive effect of oral potassium in essential hypertension</TI>
<SO>Journal of Hypertension</SO>
<YR>1983</YR>
<VL>1</VL>
<NO>Suppl 2</NO>
<PG>S165-S167</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patki-1990" NAME="Patki 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patki PS, Singh J, Gokhale SV, Bulakh PM, Shrotri DS, Patwardhan B</AU>
<TI>Efficacy of potassium and magnesium in essential hypertension: a double-blind, placebo controlled, crossover study.</TI>
<SO>BMJ</SO>
<YR>1990</YR>
<VL>301</VL>
<NO>6751</NO>
<PG>521-523</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richards-1984" NAME="Richards 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richards AM, Nicholls MG, Espiner EA, Ikram H, Maslowski AH, Hamilton EJ</AU>
<TI>Blood-pressure response to moderate sodium restriction and to potassium supplementation in mild essential hypertension</TI>
<SO>Lancet</SO>
<YR>1984</YR>
<VL>2</VL>
<NO>8360</NO>
<PG>757-761</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sacks-1994" NAME="Sacks 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sacks FM, Hebert P, Appel LJ, Borhani NO, Applegate WB, Cohen JD, Cutler JA, Kirchner KA, Kuller LH, Roth KJ, et al</AU>
<TI>Short report: the effect of fish oil on blood pressure and high-density lipoprotein-cholesterol levels in phase I of the Trials of Hypertension Prevention</TI>
<SO>Journal of Hypertension</SO>
<YR>1994</YR>
<VL>12</VL>
<NO>2</NO>
<PG>209-213</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siani-1991" NAME="Siani 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siani A, Strazzullo P, Giacco A, Pacioni D, Celentano E, Mancini M</AU>
<TI>Increasing the dietary potassium intake reduces the need for antihypertensive medications</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1991</YR>
<VL>115</VL>
<NO>10</NO>
<PG>753-759</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1983" NAME="Smith 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith SJ, Markandu ND, Sagnella GA, Poston L, Hilton PJ, MacGregor GA</AU>
<TI>Does potassium lower blood pressure by increasing sodium excretion? A metabolic study in patients with mild to moderate essential hypertension</TI>
<SO>Journal of Hypertension</SO>
<YR>1983</YR>
<VL>1</VL>
<NO>Suppl 2</NO>
<PG>S27-S30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1985" NAME="Smith 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith SJ, Markandu ND, Sagnella GA, MacGregor GA</AU>
<TI>Moderate potassium chloride supplementation in essential hypertension: is it additive to moderate sodium restriction?</TI>
<SO>BMJ</SO>
<YR>1985</YR>
<VL>290</VL>
<NO>6462</NO>
<PG>110-113</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1992" NAME="Smith 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith SR, Klotman PE, Svetlkey LP</AU>
<TI>Potassium chloride lowers blood pressure and causes natriuresis in older patients with hypertension</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1992</YR>
<VL>2</VL>
<NO>8</NO>
<PG>1302-1309</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suppa-1988" NAME="Suppa 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suppa G, Pollavini G, Alberti D, Savonitto S, GIPCIA</AU>
<TI>Effects of a low-sodium high potassium salt in hypertensive patients treated with metoprolol: a multicentre study</TI>
<SO>Journal of Hypertension</SO>
<YR>1988</YR>
<VL>6</VL>
<NO>10</NO>
<PG>787-790</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TOHP-1992" NAME="TOHP 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trials of Hypertension Prevention Collaboration Research Group</AU>
<TI>The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I</TI>
<SO>JAMA</SO>
<YR>1992</YR>
<VL>267</VL>
<NO>9</NO>
<PG>1213-1220</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valdes-1991" NAME="Valdes 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valdes G, Vio CP, Montera J, Avendano R</AU>
<TI>Potassium supplementation lowers blood pressure and increases urinary kallikein in essential hypertensives</TI>
<SO>Journal of Human Hypertension</SO>
<YR>1991</YR>
<VL>5</VL>
<NO>2</NO>
<PG>91-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whelton-1995" NAME="Whelton 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whelton PK, Buring J, Borhani NO, Cohen JD, Cook N, Cutler JA, Kiley JE, Kuller LH, Satterfield S, Sacks FM, Trials of Hypertension Prevention (TOPH) Collaborative Research Group</AU>
<TI>The effect of potassium supplementation in persons with a high-normal blood pressure: Results from phase I of the Trials of Hypertension Prevention (TOHP)</TI>
<SO>Annals of Epidemiology</SO>
<YR>1995</YR>
<VL>5</VL>
<NO>2</NO>
<PG>85-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wylie_x002d_Rosett-1993" NAME="Wylie-Rosett 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wylie-Rosett J, Wassertheil-Smoller S, Blaufox MD, Davis BR, Langford HG, Oberman A, et al</AU>
<TI>Trial of antihypertensive intervention and management: greater efficacy with weight reduction than with a sodium-potassium intervention</TI>
<SO>Journal of the American Dietetic Association</SO>
<YR>1993</YR>
<VL>93</VL>
<NO>4</NO>
<PG>408-415</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zoccali-1985" NAME="Zoccali 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zoccali C, Cumming AMM, Hutcheson MJ, Barnett P, Semple PF</AU>
<TI>Effects of potassium on sodium balance, renin, noradrenaline and arterial pressure</TI>
<SO>Journal of Hypertension</SO>
<YR>1985</YR>
<VL>3</VL>
<NO>1</NO>
<PG>67-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Australian-1989" NAME="Australian 1989" TYPE="JOURNAL_ARTICLE">
<AU>Australian National Health and Medical Research Council Dietary Salt Study Management Committee</AU>
<TI>Effects of replacing sodium intake in subjects on a low sodium diet: a crossover study</TI>
<SO>Clinical and Experimental Hypertension</SO>
<YR>1989</YR>
<VL>A11</VL>
<PG>1011-1024</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BHS-1999" NAME="BHS 1999" TYPE="JOURNAL_ARTICLE">
<AU>British Hypertension Society</AU>
<TI>Guidelines for management of hypertension: report of the third working party of the British Hypertension Society</TI>
<SO>Journal of Human Hypertension</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>9</NO>
<PG>569-592</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-1997" NAME="Brown 1997" TYPE="JOURNAL_ARTICLE">
<AU>Brown MJ</AU>
<TI>Science, Medicine and the Future: Hypertension</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>314</VL>
<NO>7089</NO>
<PG>1258-1261</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bruce-1999" NAME="Bruce 1999" TYPE="JOURNAL_ARTICLE">
<AU>Bruce MP, Saty BM, Furberg CD</AU>
<TI>British guidelines on managing hypertension</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>319</VL>
<PG>589-590</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buemi-2002" NAME="Buemi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Buemi M, Senatore M, Corica F, Aloisi C, Romeo A, Tramontana D, et al</AU>
<TI>Diet and arterial hypertension: Is the sodium ion alone important?</TI>
<SO>Medical Research Reviews</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>4</NO>
<PG>419-428</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burgess-1999" NAME="Burgess 1999" TYPE="JOURNAL_ARTICLE">
<AU>Burgess E, Lewanczuk R, Bolli P, Chockalingam A, Cutler H, Taylor G et al</AU>
<TI>Recommendations on potassium, magnesium and calcium</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1999</YR>
<VL>160</VL>
<NO>Suppl 9</NO>
<PG>S35-S45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cochrane-handbook" NAME="Cochrane handbook" TYPE="BOOK_SECTION">
<AU>Deeks JJ, Higgins, JPT, Altman DG, editors</AU>
<TI>Analysing and presenting results</TI>
<SO>Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Section 8</SO>
<YR>2005</YR>
<PB>The Cochrane Library, Issue 3, 2005. John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Conlin-2000" NAME="Conlin 2000" TYPE="JOURNAL_ARTICLE">
<AU>Conlin PR, Chow D, Miller ER, Svetkey LP, Lin PH, Harsha DW, Moore TJ, Sacks FM, Appel LJ</AU>
<TI>The effect of dietary patterns on blood pressure control in hypertensive patients: results from the Dietary Approaches to Stop Hypertension (DASH) trial</TI>
<SO>American Journal of Hypertension</SO>
<YR>2000</YR>
<VL>13</VL>
<NO>9</NO>
<PG>949-955</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curtin-2002" NAME="Curtin 2002" TYPE="JOURNAL_ARTICLE">
<AU>Curtin F, Altman DG, Elbourne D</AU>
<TI>Meta-analysis combining parallel and cross-over clinical trials</TI>
<SO>Stats in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>15</NO>
<PG>2131-2144</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-188</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Systematic reviews: identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6964</NO>
<PG>1286-1291</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickinson-2003" NAME="Dickinson 2003" TYPE="CONFERENCE_PROC">
<AU>Dickinson H, Nicolson DJ, Campbell F, Mason J</AU>
<TI>Inclusion of crossover trials in meta-analysis of nutritional supplements for raised blood pressure</TI>
<SO>XI Cochrane Colloquium: evidence, health care and culture</SO>
<YR>October 2003, Barcelona, Spain</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-2003" NAME="Egger 2003" TYPE="OTHER">
<AU>Egger M, Juni P, Bartlett C, Holenstein F, Sterne J</AU>
<TI>How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study</TI>
<SO>Health Technol. Assess.</SO>
<YR>2003</YR>
<VL>7</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne D, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-149</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Euro-2003" NAME="Euro 2003" TYPE="JOURNAL_ARTICLE">
<AU>European Society of Hypertension-European Society of Cardiology Guidelines Committee</AU>
<TI>2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension</TI>
<SO>Journal of Hypertension</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>6</NO>
<PG>1011-1053</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feldman-1999" NAME="Feldman 1999" TYPE="JOURNAL_ARTICLE">
<AU>Feldman R D et al</AU>
<TI>Canadian recommendations for the management of hypertension</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1999</YR>
<VL>161</VL>
<NO>Suppl 9</NO>
<PG>S1-S22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Galloe-1993" NAME="Galloe 1993" TYPE="JOURNAL_ARTICLE">
<AU>Galloe AM, Graudal N, Moller J, Bro H, Jorgensen M, Christensen HR</AU>
<TI>Effect of oral calcium supplementation on blood pressure in patients with previously untreated hypertension: a randomised double-blind placebo-controlled crossover study</TI>
<SO>Journal of Human Hypertension</SO>
<YR>1993</YR>
<VL>7</VL>
<PG>43-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-He-2003" NAME="He 2003" TYPE="JOURNAL_ARTICLE">
<AU>He Q, Heo M, Heshka S, Wang J, Pierson RN, Albu J, et al</AU>
<TI>Total body potassium differs by sex and race across the adult age span</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2003</YR>
<VL>78</VL>
<NO>1</NO>
<PG>72-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-560</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICSI-2003" NAME="ICSI 2003" TYPE="BOOK">
<AU>Institute for Clinical Systems Improvement</AU>
<SO>Health care guideline: hypertension diagnosis and treatment</SO>
<YR>2003</YR>
<EN>8th</EN>
<PB>ICSI</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-JNC-VII" NAME="JNC VII" TYPE="JOURNAL_ARTICLE">
<AU>Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al</AU>
<TI>The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<NO>19</NO>
<PG>2560-2572</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kawano-1998-_x0028_ii_x0029_" NAME="Kawano 1998 (ii)" TYPE="JOURNAL_ARTICLE">
<AU>Kawano Y, Yoshimi H, Matsuoka H, Takishita S, Omae T</AU>
<TI>Calcium supplementation in patients with essential hypertension: assessment by office, home and ambulatory blood pressure</TI>
<SO>Journal of Hypertension</SO>
<YR>1998</YR>
<VL>16</VL>
<PG>1693-1699</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kotchen-1998" NAME="Kotchen 1998" TYPE="JOURNAL_ARTICLE">
<AU>Kotchen TA, McCarron DA</AU>
<TI>Dietary electrolytes and blood pressure: a statement for healthcare professionals from the American Heart association nutrition committee</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>98</VL>
<NO>6</NO>
<PG>613-617</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MacMahon-1990" NAME="MacMahon 1990" TYPE="JOURNAL_ARTICLE">
<AU>MacMahon S, Cutler PR</AU>
<TI>Blood pressure stroke and coronary heart disease. Part I prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>335</VL>
<NO>8692</NO>
<PG>765-774</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCarron-1985" NAME="McCarron 1985" TYPE="JOURNAL_ARTICLE">
<AU>McCarron DA, Morris CA</AU>
<TI>Blood pressure response to oral calcium in persons with mild to moderate hypertension: a randomized, double-blind, placebo-controlled, crossover trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1985</YR>
<VL>103</VL>
<PG>825-831</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>609-613</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIH-2000" NAME="NIH 2000" TYPE="OTHER">
<AU>National High Blood Pressure Education Program Working Group</AU>
<TI>Report on High Blood Pressure in Pregnancy</TI>
<SO>NIH Publication No 00-3029</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NZGG-1997" NAME="NZGG 1997" TYPE="BOOK">
<AU>New Zealand Guideline Group</AU>
<SO>Guidelines for the management of mildly raised blood pressure in New Zealand</SO>
<YR>1997</YR>
<PB>National Health Committee</PB>
<CY>Wellington</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-PSC-2002" NAME="PSC 2002" TYPE="JOURNAL_ARTICLE">
<AU>Prospective Studies Collaboration</AU>
<TI>Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<NO>9349</NO>
<PG>1903-1913</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SAHS-2000" NAME="SAHS 2000" TYPE="JOURNAL_ARTICLE">
<AU>Southern African Hypertension Society Executive Committee</AU>
<TI>Hypertension clinical guideline 2000</TI>
<SO>S Afr Med J</SO>
<YR>2001</YR>
<VL>91</VL>
<NO>2 Pt 2</NO>
<PG>163-172</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman D</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-412</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-VHA-1999" NAME="VHA 1999" TYPE="BOOK">
<AU>Veteran's Health Administration/ Department of Defense</AU>
<SO>VHA/DOD clinical practice guideline for diagnosis and management of hypertension in the primary care setting</SO>
<YR>1999</YR>
<EN>1st</EN>
<PB>Veteran's Health Administration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whelton-1997" NAME="Whelton 1997" TYPE="JOURNAL_ARTICLE">
<AU>Whelton PK, He J, Cutler JA, Brancati FI, Appel LJ, Follmann D</AU>
<TI>Effects of oral potassium on blood pressure: Meta-analysis of randomized controlled clinical trials</TI>
<SO>JAMA</SO>
<YR>1997</YR>
<VL>277</VL>
<NO>20</NO>
<PG>1624-1632</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whelton-1999" NAME="Whelton 1999" TYPE="JOURNAL_ARTICLE">
<AU>Whelton PK, He Jiang</AU>
<TI>Potassium in preventing and treating high blood pressure</TI>
<SO>Seminars in Nephrology</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>5</NO>
<PG>494-499</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1999" NAME="WHO 1999" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organisation/ International Society of Hypertension</AU>
<TI>Guidelines for the management of hypertension</TI>
<SO>Journal of Hypertension</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>2</NO>
<PG>151-183</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2002" NAME="WHO 2002" TYPE="BOOK">
<AU>World Health Organisation</AU>
<SO>The world health report 2002: reducing risks, promoting healthy life</SO>
<YR>2002</YR>
<PB>World Health Organisation</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Chalmers-1986">
<CHAR_METHODS>
<P>Method of randomisation not reported.<BR/>2x2 factorial design: reduced sodium and reduced potassium.<BR/>Blinding: <BR/>Participant - unclear<BR/>Treatment provider - unclear<BR/>Outcome assessor - unclear.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Australia. 212 adults with currently untreated hypertension (DBP 90-100 mm Hg).<BR/>Australia. Mean age 52.3 years, 85% male, ?% white.<BR/>Inclusion criteria: without complications of hypertension or other cardiovascular diseases.<BR/>Baseline BP: 151/95<BR/>I: 151.5/94.5<BR/>C:149.8/94.5<BR/>0% baseline CVD<BR/>0% baseline diabetes.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>I: (n=105) advice to increase potassium in diet to &gt;100 mmol/d<BR/>C: (n=107) usual diet.<BR/>Potassium aggregated over high potassium and low sodium-high potassium diet; usual diet aggregated over normal diet and low sodium diet.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BP at 12 weeks, measured seated in clinic as mean of two readings. SD of final values not reported. Change scores (SD) reported.<BR/>Withdrawn:<BR/>I: 5/105 (5%)<BR/>C: 7/107 (7%)<BR/>Reasons for withdrawal not reported.<BR/>Adverse effects not reported.<BR/>Deaths and cardiovascular events not reported.<BR/>Serum potassium not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Loss to follow up:<BR/>I: 5/105 (5%)<BR/>C: 7/107 (7%<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cushman-1988">
<CHAR_METHODS>
<P>Method of randomisation not reported.<BR/>Parallel design.<BR/>Blinding: <BR/>Participant - yes<BR/>Treatment provider - unclear.<BR/>Outcome assessor - unclear.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>USA. 58 adults (26-69 years) with mild currently untreated hypertension (DBP 90-105 mm Hg).<BR/>USA. Mean age not reported, 100% male, 47% white.<BR/>Baseline DBP: 95.1<BR/>I: 95.3<BR/>C:94.8<BR/>% baseline CVD not reported<BR/>% baseline diabetes not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>I: (n=?) 80 mmol/d oral potassium chloride<BR/>C: (n=?) placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BP at 10 weeks, method of measurement not reported. Final value (SD) of DBP reported in I arm only. SD of change score for DBP not reported. Final values and change scores of SBP not reported. <BR/>Withdrawn:<BR/>not reported.<BR/>Adverse effects not reported.<BR/>Deaths and cardiovascular events not reported.<BR/>Serum potassium not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Loss to follow up:<BR/>not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Obel-1989">
<CHAR_METHODS>
<P>Method of randomisation not reported.<BR/>Parallel design.<BR/>Blinding: <BR/>Participant - yes<BR/>Treatment provider - yes.<BR/>Outcome assessor - unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Kenya. 48 adults (23-56 years) with treatment naive hypertension (SBP &gt;160 mm Hg and DBP 90-109 mm Hg).<BR/>Kenya. Mean age 41 years, 44% male, 0% white.<BR/>Baseline BP: 174/100<BR/>I: 175/100<BR/>C:173/100<BR/>% baseline CVD not reported<BR/>% baseline diabetes not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>I: (n=24) 64 mmol/d potassium (8 tablets)<BR/>C: (n=24) matching placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BP at 16 weeks, measured supine in clinic as mean of two readings. Final values (SD) reported.<BR/>Withdrawn:<BR/>not reported.<BR/>Adverse effects not reported.<BR/>Deaths and cardiovascular events not reported.<BR/>Serum potassium at end of trial:<BR/>T: 4.0 (0.2) mmol/l<BR/>C: "similar"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Loss to follow up:<BR/>I: 0/24 (0%)<BR/>C: 0/24 (0%)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Overlack-1991">
<CHAR_METHODS>
<P>Method of randomisation not reported.<BR/>Crossover design.<BR/>Blinding: <BR/>Participant - no<BR/>Treatment provider - no<BR/>Outcome assessor - yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Germany. 12 adults (25-59 years) with currently untreated essential hypertension (DBP 95-110 mm Hg).<BR/>Germany. Mean age 36.5 years, 67% male, ?% white.<BR/>Inclusion criteria: without diabetes, cardiovascular disease, renal disease. <BR/>Baseline BP: 150/100<BR/>0% baseline CVD<BR/>0% baseline diabetes.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>I: 120 mmol/d potassium as 50% citrate and 50% bicarbonate.<BR/>C: placebo<BR/>No washout period.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BP at 8 weeks, measured seated in clinic as mean of three readings. Final values (SD) reported; SD of crossover treatment effect not reported and therefore imputed.<BR/>Withdrawn:<BR/>0/12 (0%)<BR/>Adverse effects not reported.<BR/>Deaths and cardiovascular events not reported.<BR/>Serum potassium at end of trial:<BR/>T: 4.33 (SE 0.1) mmol/l<BR/>C: 4.06 (SE 0.1) mmol/l</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Loss to follow up:<BR/>0/12 (0%)<BR/>Carryover effects not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Siani-1987">
<CHAR_METHODS>
<P>Method of randomisation not reported.<BR/>Parallel design.<BR/>Blinding: <BR/>Participant - yes<BR/>Treatment provider - yes<BR/>Outcome assessor - yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Italy. 37 adults (21-61 years) with currently untreated essential hypertension (SBP &gt;160 mm Hg or DBP &gt;90 mm Hg).<BR/>Italy. Mean age 45 years, 62% male, ?% white.<BR/>Inclusion criteria: without comorbidity. No patients had recently taken diuretics or other drugs known to affect potassium metabolism, normal serum potassium, normal dietary intake of sodium.<BR/>Baseline BP: 145/92<BR/>I: 144.8/91.6<BR/>C:145.1/91.5<BR/>0% baseline CVD<BR/>0% baseline diabetes.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>I: (n=18) 48 mmol/d potassium (6 tablets)<BR/>C: (n=19) matching placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BP at 15 weeks, measured supine in clinic as mean of three readings. Final valaues (SD) reported.<BR/>Withdrawn:<BR/>I: 0/18(0%)<BR/>C: 0/19(0%)<BR/>No adverse effects in either group.<BR/>Deaths and cardiovascular events not reported.<BR/>Serum potassium at end of trial:<BR/>T: 4.4 (0.1) mmol/l<BR/>C: 4.3 (0.1) mmol/l</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Loss to follow up:<BR/>I: 0/18(0%)<BR/>C: 0/19(0%)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Svetkey-1987">
<CHAR_METHODS>
<P>Randomisation by "Computer generated table of random numbers".<BR/>Parallel design.<BR/>Blinding:<BR/>Participant - yes<BR/>Treatment provider - yes<BR/>Outcome assessor - yes.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>USA. 116 adults with currently untreated essential hypertension (DBP 90-105 mm Hg).<BR/>USA. Mean age 51.1 years, 74% male, 86% white.<BR/>Inclusion criteria: without cardiac disease, renal disease, cerebrovascular accident, terminal illness or baseline serum potassium &gt;5 mmol/l.<BR/>Baseline BP: 145/95<BR/>I: 147.5/95.2<BR/>C:142.1/94.1<BR/>0% baseline CVD<BR/>0% baseline diabetes.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>I: (n=59) 120 mmol/d potassium chloride (15 tablets)<BR/>C: (n=57) matching placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BP at 8 weeks, measured seated in clinic. Final values (SD) reported.<BR/>Withdrawn:<BR/>I: 5/59(9%)<BR/>1 due to gastro-intestinal side effects and decreased energy, 4 for unspecified reasons.<BR/>C: 10/57(18%)<BR/>1 because of gastro-intestinal side effects and anxiety, 1 because of gastro-intestinal side effects, 4 because of high blood pressure, 1 because of polycythemia, 3 for unspecified reasons.<BR/>Adverse effects: stomach pain (11 participants in I; 5 participants in C); change in bowel habits (6 in I, 8 in C); flatulence (12 in I, 6 in C); lethargy (1 in I, 1 in C); anxiety (1 in I, 1 in C); skin rash (1 in C); palpitations (1 in C); headache (2 in I, 3 in C); dizziness (1 in C).<BR/>Deaths and cardiovascular events not reported.<BR/>Serum potassium at end of trial:<BR/>T: 4.7 (0.4) mmol/l<BR/>C: not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Loss to follow up:<BR/>I: 5/59(9%)<BR/>C: 10/57(18%)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Appel-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Normotensive subjects</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barden-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Normotensive subjects</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barden-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Normotensive subjects</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bompiani-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brancati-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bulpitt-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Antihypertensive medication varied during trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fotherby-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Geleijnse-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention consisted of multiple supplements</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Geleijnse-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention consisted of multiple supplements</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Grimm-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Normotensive subjects</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Grimm-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Normotensive subjects</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Grobbee-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gruchow-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study design epidemiology survey</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hebert-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Normotensive subjects</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hollis-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Normotensive subjects</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iimura-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Intersalt-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study design observational</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jula-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial of multiple interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kaplan-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kawamura-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kawano-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Khaw-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up and normotensive subjects</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kromhout-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study design survey</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Langford-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Antihypertensive medication varied during trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MacGregor-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Matlou-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MRC-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Control group on drugs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Omvik-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Combined increased potassium with decreased sodium intake</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Overlack-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Patki-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients not randomly allocated to sequence of treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Richards-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sacks-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Normotensive subjects</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siani-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Normotensive subjects</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smith-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smith-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smith-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Suppa-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-TOHP-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Normotensive subjects</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Valdes-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Whelton-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Normotensive subjects</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wylie_x002d_Rosett-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Antihypertensive medication varied during trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zoccali-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Chalmers-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cushman-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Obel-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Overlack-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Siani-1987">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Svetkey-1987">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Potassium versus control (parallel trials only)</NAME>
<CONT_OUTCOME CHI2="181.14817186030865" CI_END="2.227799098291225" CI_START="-31.251640267464406" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-14.51192058458659" ESTIMABLE="YES" I2="98.34389717037088" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="-2.220446049250313E-16" P_Q="1.0" P_Z="0.08929602224936935" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="284.51954691138303" TOTALS="YES" TOTAL_1="196" TOTAL_2="190" UNITS="" WEIGHT="100.0" Z="1.6991229382047457">
<NAME>Systolic BP</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours potassium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.5191001042069803" CI_START="-6.080899895793019" EFFECT_SIZE="-4.3" ESTIMABLE="YES" MEAN_1="-7.6" MEAN_2="-3.3" ORDER="1149" SD_1="6.45" SD_2="6.4" SE="0.9086390922693124" STUDY_ID="STD-Chalmers-1986" TOTAL_1="100" TOTAL_2="100" WEIGHT="25.5640496124167"/>
<CONT_DATA CI_END="-34.1164503846953" CI_START="-43.8835496153047" EFFECT_SIZE="-39.0" ESTIMABLE="YES" MEAN_1="133.0" MEAN_2="172.0" ORDER="1150" SD_1="10.0" SD_2="7.0" SE="2.4916527312876755" STUDY_ID="STD-Obel-1989" TOTAL_1="24" TOTAL_2="24" WEIGHT="25.09074164220526"/>
<CONT_DATA CI_END="-6.238670843682436" CI_START="-21.761329156317565" EFFECT_SIZE="-14.0" ESTIMABLE="YES" MEAN_1="131.8" MEAN_2="145.8" ORDER="1151" SD_1="12.7" SD_2="11.3" SE="3.959934579174892" STUDY_ID="STD-Siani-1987" TOTAL_1="18" TOTAL_2="19" WEIGHT="24.299010168581827"/>
<CONT_DATA CI_END="4.182838623000506" CI_START="-5.982838623000517" EFFECT_SIZE="-0.9000000000000057" ESTIMABLE="YES" MEAN_1="141.1" MEAN_2="142.0" ORDER="1152" SD_1="13.0" SD_2="13.0" SE="2.5933326648312387" STUDY_ID="STD-Svetkey-1987" TOTAL_1="54" TOTAL_2="47" WEIGHT="25.04619857679621"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="142.4256962819616" CI_END="1.0617020324668625" CI_START="-16.072994903970013" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.505646435751575" ESTIMABLE="YES" I2="97.89363852288223" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="-4.440892098500626E-16" P_Q="1.0" P_Z="0.08596511060947529" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="73.36506222883281" TOTALS="YES" TOTAL_1="196" TOTAL_2="190" UNITS="" WEIGHT="100.0" Z="1.7170769636995509">
<NAME>Diastolic BP</NAME>
<GROUP_LABEL_1>Potassium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours potassium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.12100828402991803" CI_START="-2.878991715970081" EFFECT_SIZE="-1.4999999999999996" ESTIMABLE="YES" MEAN_1="-4.6" MEAN_2="-3.1" ORDER="1153" SD_1="5.0" SD_2="4.95" SE="0.7035801304755558" STUDY_ID="STD-Chalmers-1986" TOTAL_1="100" TOTAL_2="100" WEIGHT="25.869430330195286"/>
<CONT_DATA CI_END="-14.736828531847657" CI_START="-19.263171468152343" EFFECT_SIZE="-17.0" ESTIMABLE="YES" MEAN_1="83.0" MEAN_2="100.0" ORDER="1154" SD_1="4.0" SD_2="4.0" SE="1.1547005383792515" STUDY_ID="STD-Obel-1989" TOTAL_1="24" TOTAL_2="24" WEIGHT="25.579108712693603"/>
<CONT_DATA CI_END="-4.667569881188478" CI_START="-16.332430118811523" EFFECT_SIZE="-10.5" ESTIMABLE="YES" MEAN_1="82.0" MEAN_2="92.5" ORDER="1155" SD_1="8.9" SD_2="9.2" SE="2.9757843331902967" STUDY_ID="STD-Siani-1987" TOTAL_1="18" TOTAL_2="19" WEIGHT="23.238994643459634"/>
<CONT_DATA CI_END="1.5538911849900492" CI_START="-4.153891184990072" EFFECT_SIZE="-1.3000000000000114" ESTIMABLE="YES" MEAN_1="91.1" MEAN_2="92.4" ORDER="1156" SD_1="8.3" SD_2="6.3" SE="1.4560936871805756" STUDY_ID="STD-Svetkey-1987" TOTAL_1="54" TOTAL_2="47" WEIGHT="25.31246631365148"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.7413780957823994" CI_END="0.023228296778537667" CI_START="-0.07339786617941679" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.025084784700439566" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-1.6339826337986123" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="3" P_CHI2="0.4186633341476179" P_Q="0.0" P_Z="0.3088495734890274" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="182" TOTAL_2="183" WEIGHT="100.0" Z="1.0176389720493508">
<NAME>Total withdrawal from treatment</NAME>
<GROUP_LABEL_1>Potassium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.044281017078442814" CI_START="-0.07988404333567467" EFFECT_SIZE="-0.01780151312861593" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1157" O_E="0.0" SE="0.03167534235157269" STUDY_ID="STD-Chalmers-1986" TOTAL_1="105" TOTAL_2="107" VAR="0.0010033273130893344" WEIGHT="60.560668373678254"/>
<DICH_DATA CI_END="0.09930932864748786" CI_START="-0.09930932864748786" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1158" O_E="0.0" SE="0.05066895587410134" STUDY_ID="STD-Siani-1987" TOTAL_1="18" TOTAL_2="19" VAR="0.0025673430893716287" WEIGHT="23.667336449811508"/>
<DICH_DATA CI_END="0.03095977329717982" CI_START="-0.21234544085590712" EFFECT_SIZE="-0.09069283377936366" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1159" O_E="0.0" SE="0.06206879720041986" STUDY_ID="STD-Svetkey-1987" TOTAL_1="59" TOTAL_2="57" VAR="0.0038525355859068485" WEIGHT="15.771995176510233"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Potassium versus control (all trials)</NAME>
<IV_OUTCOME CHI2="189.3518144860713" CI_END="2.6841184370996327" CI_START="-25.1833270311023" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="-11.249604297001333" ESTIMABLE="YES" I2="97.88753014548259" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.42880167522422097" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="-6.661338147750939E-16" P_Q="1.0" P_Z="0.11355670620863083" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="244.59879647612703" TOTALS="YES" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="1.5824069190416747">
<NAME>Systolic BP</NAME>
<GROUP_LABEL_1>Potassium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours potassium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD</EFFECT_MEASURE>
<IV_DATA CI_END="-2.5164327740685506" CI_START="-6.083567225931449" EFFECT_SIZE="-4.3" ESTIMABLE="YES" ESTIMATE="-4.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1160" SE="0.91" STUDY_ID="STD-Chalmers-1986" TOTAL_1="1" TOTAL_2="1" WEIGHT="20.59282794651492"/>
<IV_DATA CI_END="-34.11968967849526" CI_START="-43.88031032150474" EFFECT_SIZE="-39.0" ESTIMABLE="YES" ESTIMATE="-39.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1161" SE="2.49" STUDY_ID="STD-Obel-1989" TOTAL_1="1" TOTAL_2="1" WEIGHT="20.151738797866265"/>
<IV_DATA CI_END="8.676225320538787" CI_START="-4.676225320538786" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1162" SE="3.4063" STUDY_ID="STD-Overlack-1991" TOTAL_1="1" TOTAL_2="1" WEIGHT="19.726779028966472"/>
<IV_DATA CI_END="-6.238542621221385" CI_START="-21.761457378778616" EFFECT_SIZE="-14.0" ESTIMABLE="YES" ESTIMATE="-14.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1163" SE="3.96" STUDY_ID="STD-Siani-1987" TOTAL_1="1" TOTAL_2="1" WEIGHT="19.41765081429623"/>
<IV_DATA CI_END="4.17630671995874" CI_START="-5.976306719958741" EFFECT_SIZE="-0.9" ESTIMABLE="YES" ESTIMATE="-0.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1164" SE="2.59" STUDY_ID="STD-Svetkey-1987" TOTAL_1="1" TOTAL_2="1" WEIGHT="20.11100341235611"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="320.243483887887" CI_END="2.4163437723742955" CI_START="-12.467778345757912" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="-5.025717286691808" ESTIMABLE="YES" I2="98.75095038580072" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.38315872126712613" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="-4.440892098500626E-16" P_Q="1.0" P_Z="0.18563981600262022" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="69.62156918010818" TOTALS="YES" TOTAL_1="5" TOTAL_2="5" WEIGHT="99.99999999999997" Z="1.3235882909609453">
<NAME>Diastolic BP</NAME>
<GROUP_LABEL_1>Potassium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours potassium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD</EFFECT_MEASURE>
<IV_DATA CI_END="-0.10842557097656158" CI_START="-2.8915744290234384" EFFECT_SIZE="-1.5" ESTIMABLE="YES" ESTIMATE="-1.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1165" SE="0.71" STUDY_ID="STD-Chalmers-1986" TOTAL_1="1" TOTAL_2="1" WEIGHT="20.55953354717609"/>
<IV_DATA CI_END="-14.746041417778937" CI_START="-19.253958582221063" EFFECT_SIZE="-17.0" ESTIMABLE="YES" ESTIMATE="-17.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1166" SE="1.15" STUDY_ID="STD-Obel-1989" TOTAL_1="1" TOTAL_2="1" WEIGHT="20.322361892808587"/>
<IV_DATA CI_END="5.4617543272138045" CI_START="3.5382456727861955" EFFECT_SIZE="4.5" ESTIMABLE="YES" ESTIMATE="4.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1167" SE="0.4907" STUDY_ID="STD-Overlack-1991" TOTAL_1="1" TOTAL_2="1" WEIGHT="20.637023103466362"/>
<IV_DATA CI_END="-4.678906965916038" CI_START="-16.32109303408396" EFFECT_SIZE="-10.5" ESTIMABLE="YES" ESTIMATE="-10.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1168" SE="2.97" STUDY_ID="STD-Siani-1987" TOTAL_1="1" TOTAL_2="1" WEIGHT="18.379725461169095"/>
<IV_DATA CI_END="1.5419477775830785" CI_START="-4.141947777583079" EFFECT_SIZE="-1.3" ESTIMABLE="YES" ESTIMATE="-1.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1169" SE="1.45" STUDY_ID="STD-Svetkey-1987" TOTAL_1="1" TOTAL_2="1" WEIGHT="20.101355995379848"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.8245540204141316" CI_END="0.378613381191381" CI_START="0.015340737655669928" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.19697705942352545" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.42180404099324115" LOG_CI_START="-1.8141537569395372" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.705584350213592" NO="3" P_CHI2="0.3638520974200522" P_Q="1.0" P_Z="0.033544941451803846" Q="0.0" RANDOM="YES" SCALE="0.5" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2" TOTAL_2="2" WEIGHT="100.0" Z="2.1254996715036927">
<NAME>Serum potassium (mmol/L)</NAME>
<GROUP_LABEL_1>Net decrease K</GROUP_LABEL_1>
<GROUP_LABEL_2>Net increase K</GROUP_LABEL_2>
<GRAPH_LABEL_1>Net decrease K</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Net increase K</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD in serum K</EFFECT_MEASURE>
<IV_DATA CI_END="0.5104875809030647" CI_START="0.02951241909693536" EFFECT_SIZE="0.27" ESTIMABLE="YES" ESTIMATE="0.27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1170" SE="0.1227" STUDY_ID="STD-Overlack-1991" TOTAL_1="1" TOTAL_2="1" WEIGHT="57.045329072662035"/>
<IV_DATA CI_END="0.3771389074139637" CI_START="-0.17713890741396368" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1171" SE="0.1414" STUDY_ID="STD-Siani-1987" TOTAL_1="1" TOTAL_2="1" WEIGHT="42.954670927337965"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Potassium vs control (all trials), subgrouped by baseline blood pressure</NAME>
<IV_OUTCOME CHI2="189.3518144860713" CI_END="2.684118437099629" CI_START="-25.183327031102294" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="-11.249604297001333" ESTIMABLE="YES" I2="97.88753014548259" I2_Q="38.045954860978284" ID="CMP-003.01" LOG_CI_END="0.4288016752242204" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="-6.661338147750939E-16" P_Q="0.20391653528582865" P_Z="0.1135567062086308" Q="1.6140996084372716" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="244.59879647612692" TOTALS="YES" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="1.582406919041675">
<NAME>Systolic BP</NAME>
<GROUP_LABEL_1>Potassium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours potassium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD in SBP</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="180.07302977689574" CI_END="9.409404866943923" CI_START="-36.99440915393557" DF="2.0" EFFECT_SIZE="-13.792502143495824" ESTIMABLE="YES" I2="98.88933950715555" ID="CMP-003.01.01" LOG_CI_END="0.9735621557146309" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="2.220446049250313E-16" P_Z="0.2439739039618477" STUDIES="3" TAU2="414.2450788700795" TOTAL_1="3" TOTAL_2="3" WEIGHT="60.471345773347664" Z="1.1651114473383521">
<NAME>Baseline BP &gt; 145/95</NAME>
<IV_DATA CI_END="-2.5164327740685506" CI_START="-6.083567225931449" EFFECT_SIZE="-4.3" ESTIMABLE="YES" ESTIMATE="-4.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1172" SE="0.91" STUDY_ID="STD-Chalmers-1986" TOTAL_1="1" TOTAL_2="1" WEIGHT="20.592827946514927"/>
<IV_DATA CI_END="-34.11968967849526" CI_START="-43.88031032150474" EFFECT_SIZE="-39.0" ESTIMABLE="YES" ESTIMATE="-39.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1173" SE="2.49" STUDY_ID="STD-Obel-1989" TOTAL_1="1" TOTAL_2="1" WEIGHT="20.151738797866265"/>
<IV_DATA CI_END="8.676225320538787" CI_START="-4.676225320538786" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1174" SE="3.4063" STUDY_ID="STD-Overlack-1991" TOTAL_1="1" TOTAL_2="1" WEIGHT="19.726779028966472"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="7.664685100738284" CI_END="5.712701243586026" CI_START="-19.927701243586025" DF="1.0" EFFECT_SIZE="-7.107499999999999" ESTIMABLE="YES" I2="86.95314958335761" ID="CMP-003.01.02" LOG_CI_END="0.7568415124108594" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.005631220492666955" P_Z="0.27721318146994745" STUDIES="2" TAU2="74.61014999999998" TOTAL_1="2" TOTAL_2="2" WEIGHT="39.52865422665234" Z="1.0866010412346583">
<NAME>Baseline BP &lt;= 145/95</NAME>
<IV_DATA CI_END="-6.238542621221385" CI_START="-21.761457378778616" EFFECT_SIZE="-14.0" ESTIMABLE="YES" ESTIMATE="-14.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1175" SE="3.96" STUDY_ID="STD-Siani-1987" TOTAL_1="1" TOTAL_2="1" WEIGHT="19.417650814296234"/>
<IV_DATA CI_END="4.17630671995874" CI_START="-5.976306719958741" EFFECT_SIZE="-0.9" ESTIMABLE="YES" ESTIMATE="-0.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1176" SE="2.59" STUDY_ID="STD-Svetkey-1987" TOTAL_1="1" TOTAL_2="1" WEIGHT="20.11100341235611"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="320.24348388788695" CI_END="2.4163437723742938" CI_START="-12.467778345757912" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="-5.025717286691809" ESTIMABLE="YES" I2="98.7509503858007" I2_Q="84.83068458816213" ID="CMP-003.02" LOG_CI_END="0.3831587212671258" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.0" P_Q="0.010242368531304225" P_Z="0.18563981600262008" Q="6.592255305203935" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="69.62156918010817" TOTALS="YES" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="1.3235882909609458">
<NAME>Diastolic BP</NAME>
<GROUP_LABEL_1>Potassium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours potassium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD in DBP</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="305.9027253693978" CI_END="5.631772350378399" CI_START="-14.863734905832807" DF="2.0" EFFECT_SIZE="-4.615981277727204" ESTIMABLE="YES" I2="99.34619739082584" ID="CMP-003.02.01" LOG_CI_END="0.7506450912738533" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="4.440892098500626E-16" P_Z="0.37732113986052906" STUDIES="3" TAU2="81.32639812240237" TOTAL_1="3" TOTAL_2="3" WEIGHT="61.51891854345104" Z="0.8828429513414207">
<NAME>Baseline BP &gt;145/95</NAME>
<IV_DATA CI_END="-0.10842557097656158" CI_START="-2.8915744290234384" EFFECT_SIZE="-1.5" ESTIMABLE="YES" ESTIMATE="-1.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1177" SE="0.71" STUDY_ID="STD-Chalmers-1986" TOTAL_1="1" TOTAL_2="1" WEIGHT="20.559533547176095"/>
<IV_DATA CI_END="-14.746041417778937" CI_START="-19.253958582221063" EFFECT_SIZE="-17.0" ESTIMABLE="YES" ESTIMATE="-17.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1178" SE="1.15" STUDY_ID="STD-Obel-1989" TOTAL_1="1" TOTAL_2="1" WEIGHT="20.322361892808587"/>
<IV_DATA CI_END="5.4617543272138045" CI_START="3.5382456727861955" EFFECT_SIZE="4.5" ESTIMABLE="YES" ESTIMATE="4.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1179" SE="0.4907" STUDY_ID="STD-Overlack-1991" TOTAL_1="1" TOTAL_2="1" WEIGHT="20.63702310346636"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="7.74850321328524" CI_END="3.4525173996048864" CI_START="-14.52225653003967" DF="1.0" EFFECT_SIZE="-5.534869565217392" ESTIMABLE="YES" I2="87.09428166351606" ID="CMP-003.02.02" LOG_CI_END="0.5381358759641658" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.005375721660272448" P_Z="0.22741635724513753" STUDIES="2" TAU2="36.8583" TOTAL_1="2" TOTAL_2="2" WEIGHT="38.48108145654895" Z="1.207041050909893">
<NAME>Baseline BP &lt;=145/95</NAME>
<IV_DATA CI_END="-4.678906965916038" CI_START="-16.32109303408396" EFFECT_SIZE="-10.5" ESTIMABLE="YES" ESTIMATE="-10.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1180" SE="2.97" STUDY_ID="STD-Siani-1987" TOTAL_1="1" TOTAL_2="1" WEIGHT="18.3797254611691"/>
<IV_DATA CI_END="1.5419477775830785" CI_START="-4.141947777583079" EFFECT_SIZE="-1.3" ESTIMABLE="YES" ESTIMATE="-1.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1181" SE="1.45" STUDY_ID="STD-Svetkey-1987" TOTAL_1="1" TOTAL_2="1" WEIGHT="20.101355995379848"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Potassium vs control (all trials), subgrouped by potassium dose</NAME>
<IV_OUTCOME CHI2="189.3518144860713" CI_END="2.684118437099629" CI_START="-25.183327031102294" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="-11.249604297001333" ESTIMABLE="YES" I2="97.88753014548259" I2_Q="99.36065057961977" ID="CMP-004.01" LOG_CI_END="0.4288016752242204" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="-6.661338147750939E-16" P_Q="-1.3322676295501878E-15" P_Z="0.1135567062086308" Q="156.40899453780554" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="244.59879647612692" TOTALS="YES" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="1.582406919041675">
<NAME>Systolic BP</NAME>
<GROUP_LABEL_1>Potassium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours potassium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD in SBP</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="4.380139717753531" CI_END="1.5436957710528825" CI_START="-5.749893817069237" DF="2.0" EFFECT_SIZE="-2.1030990230081774" ESTIMABLE="YES" I2="54.339356073651636" ID="CMP-004.01.01" LOG_CI_END="0.1885617144118973" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.11190901814190568" P_Z="0.2583468286546774" STUDIES="3" TAU2="5.782537711896739" TOTAL_1="3" TOTAL_2="3" WEIGHT="60.430610387837504" Z="1.1303071803574551">
<NAME>Potassium dose &gt;100 mmol/day</NAME>
<IV_DATA CI_END="-2.5164327740685506" CI_START="-6.083567225931449" EFFECT_SIZE="-4.3" ESTIMABLE="YES" ESTIMATE="-4.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1182" SE="0.91" STUDY_ID="STD-Chalmers-1986" TOTAL_1="1" TOTAL_2="1" WEIGHT="20.592827946514927"/>
<IV_DATA CI_END="8.676225320538787" CI_START="-4.676225320538786" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1183" SE="3.4063" STUDY_ID="STD-Overlack-1991" TOTAL_1="1" TOTAL_2="1" WEIGHT="19.726779028966472"/>
<IV_DATA CI_END="4.17630671995874" CI_START="-5.976306719958741" EFFECT_SIZE="-0.9" ESTIMABLE="YES" ESTIMATE="-0.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1184" SE="2.59" STUDY_ID="STD-Svetkey-1987" TOTAL_1="1" TOTAL_2="1" WEIGHT="20.11100341235611"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="28.56268023051225" CI_END="-2.192899531359" CI_START="-51.186360468641" DF="1.0" EFFECT_SIZE="-26.68963" ESTIMABLE="YES" I2="96.498928" ID="CMP-004.01.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="9.071733808596605E-8" P_Z="0.03272703366492125" STUDIES="2" TAU2="301.5591499999999" TOTAL_1="2" TOTAL_2="2" WEIGHT="39.569389612162496" Z="2.1354161375806573">
<NAME>Potassium dose &lt;= 100 mmol/day</NAME>
<IV_DATA CI_END="-34.11968967849526" CI_START="-43.88031032150474" EFFECT_SIZE="-39.0" ESTIMABLE="YES" ESTIMATE="-39.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1185" SE="2.49" STUDY_ID="STD-Obel-1989" TOTAL_1="1" TOTAL_2="1" WEIGHT="20.151738797866265"/>
<IV_DATA CI_END="-6.238542621221385" CI_START="-21.761457378778616" EFFECT_SIZE="-14.0" ESTIMABLE="YES" ESTIMATE="-14.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1186" SE="3.96" STUDY_ID="STD-Siani-1987" TOTAL_1="1" TOTAL_2="1" WEIGHT="19.417650814296234"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="320.243483887887" CI_END="2.4163437723742955" CI_START="-12.467778345757914" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="-5.025717286691809" ESTIMABLE="YES" I2="98.75095038580072" I2_Q="99.61710788503106" ID="CMP-004.02" LOG_CI_END="0.38315872126712613" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="-4.440892098500626E-16" P_Q="9.992007221626409E-16" P_Z="0.18563981600262022" Q="261.17017324348154" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="69.62156918010818" TOTALS="YES" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.00000000000003" Z="1.3235882909609453">
<NAME>Diastolic BP</NAME>
<GROUP_LABEL_1>Potassium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours potassium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD in SBP</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="54.908040616604126" CI_END="5.254954487668107" CI_START="-3.9624846334725268" DF="2.0" EFFECT_SIZE="0.6462349270977901" ESTIMABLE="YES" I2="96.35754622175462" ID="CMP-004.02.01" LOG_CI_END="0.7205689590245478" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.18960957334418507" NO="1" P_CHI2="1.1934897514720433E-12" P_Z="0.7834497186595754" STUDIES="3" TAU2="15.67798174632977" TOTAL_1="3" TOTAL_2="3" WEIGHT="61.297912646022326" Z="0.27482626486971534">
<NAME>Potassium dose &gt; 100mmol/day</NAME>
<IV_DATA CI_END="-0.10842557097656158" CI_START="-2.8915744290234384" EFFECT_SIZE="-1.5" ESTIMABLE="YES" ESTIMATE="-1.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1187" SE="0.71" STUDY_ID="STD-Chalmers-1986" TOTAL_1="1" TOTAL_2="1" WEIGHT="20.5595335471761"/>
<IV_DATA CI_END="5.4617543272138045" CI_START="3.5382456727861955" EFFECT_SIZE="4.5" ESTIMABLE="YES" ESTIMATE="4.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1188" SE="0.4907" STUDY_ID="STD-Overlack-1991" TOTAL_1="1" TOTAL_2="1" WEIGHT="20.637023103466365"/>
<IV_DATA CI_END="1.5419477775830785" CI_START="-4.141947777583079" EFFECT_SIZE="-1.3" ESTIMABLE="YES" ESTIMATE="-1.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1189" SE="1.45" STUDY_ID="STD-Svetkey-1987" TOTAL_1="1" TOTAL_2="1" WEIGHT="20.101355995379855"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="4.165270027801328" CI_END="-8.0580391810738" CI_START="-20.595560818926202" DF="1.0" EFFECT_SIZE="-14.326800000000002" ESTIMABLE="YES" I2="75.9919526627219" ID="CMP-004.02.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.04126096145808278" P_Z="7.486854256982629E-6" STUDIES="2" TAU2="16.0533" TOTAL_1="2" TOTAL_2="2" WEIGHT="38.702087353977696" Z="4.479356100001655">
<NAME>Potassium dose &lt;= 100mmol/day</NAME>
<IV_DATA CI_END="-14.746041417778937" CI_START="-19.253958582221063" EFFECT_SIZE="-17.0" ESTIMABLE="YES" ESTIMATE="-17.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1190" SE="1.15" STUDY_ID="STD-Obel-1989" TOTAL_1="1" TOTAL_2="1" WEIGHT="20.322361892808594"/>
<IV_DATA CI_END="-4.678906965916038" CI_START="-16.32109303408396" EFFECT_SIZE="-10.5" ESTIMABLE="YES" ESTIMATE="-10.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1191" SE="2.97" STUDY_ID="STD-Siani-1987" TOTAL_1="1" TOTAL_2="1" WEIGHT="18.3797254611691"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Potassium vs control (all trials except Obel 1989)</NAME>
<IV_OUTCOME CHI2="11.01856507398387" CI_END="0.8106843851082481" CI_START="-8.562373058696302" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="-3.8758443367940267" ESTIMABLE="YES" I2="72.7732242823219" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-0.09114819200879114" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.011625956074962085" P_Q="1.0" P_Z="0.10503355326942707" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="15.539129433273375" TOTALS="YES" TOTAL_1="4" TOTAL_2="4" WEIGHT="100.0" Z="1.6209257982988265">
<NAME>Systolic BP</NAME>
<GROUP_LABEL_1>Potassium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours potassium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD</EFFECT_MEASURE>
<IV_DATA CI_END="-2.5164327740685506" CI_START="-6.083567225931449" EFFECT_SIZE="-4.3" ESTIMABLE="YES" ESTIMATE="-4.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1192" SE="0.91" STUDY_ID="STD-Chalmers-1986" TOTAL_1="1" TOTAL_2="1" WEIGHT="34.932624343710124"/>
<IV_DATA CI_END="8.676225320538787" CI_START="-4.676225320538786" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1193" SE="3.4063" STUDY_ID="STD-Overlack-1991" TOTAL_1="1" TOTAL_2="1" WEIGHT="21.065142036578177"/>
<IV_DATA CI_END="-6.238542621221385" CI_START="-21.761457378778616" EFFECT_SIZE="-14.0" ESTIMABLE="YES" ESTIMATE="-14.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1194" SE="3.96" STUDY_ID="STD-Siani-1987" TOTAL_1="1" TOTAL_2="1" WEIGHT="18.313162047088934"/>
<IV_DATA CI_END="4.179834655130913" CI_START="-5.979834655130913" EFFECT_SIZE="-0.9" ESTIMABLE="YES" ESTIMATE="-0.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1195" SE="2.5918" STUDY_ID="STD-Svetkey-1987" TOTAL_1="1" TOTAL_2="1" WEIGHT="25.689071572622755"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="73.11999901888903" CI_END="3.090246286330328" CI_START="-6.156486178535714" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="-1.5331199461026934" ESTIMABLE="YES" I2="95.89715530599909" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.4899930931891834" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="9.992007221626409E-16" P_Q="1.0" P_Z="0.5157380766775673" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="19.80398201084208" TOTALS="YES" TOTAL_1="4" TOTAL_2="4" WEIGHT="100.0" Z="0.6499290186579004">
<NAME>Diastolic BP</NAME>
<GROUP_LABEL_1>Potassium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours potassium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD</EFFECT_MEASURE>
<IV_DATA CI_END="-0.10842557097656158" CI_START="-2.8915744290234384" EFFECT_SIZE="-1.5" ESTIMABLE="YES" ESTIMATE="-1.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1196" SE="0.71" STUDY_ID="STD-Chalmers-1986" TOTAL_1="1" TOTAL_2="1" WEIGHT="27.400059307928874"/>
<IV_DATA CI_END="5.4617543272138045" CI_START="3.5382456727861955" EFFECT_SIZE="4.5" ESTIMABLE="YES" ESTIMATE="4.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1197" SE="0.4907" STUDY_ID="STD-Overlack-1991" TOTAL_1="1" TOTAL_2="1" WEIGHT="27.759993910829166"/>
<IV_DATA CI_END="-4.678906965916038" CI_START="-16.32109303408396" EFFECT_SIZE="-10.5" ESTIMABLE="YES" ESTIMATE="-10.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1198" SE="2.97" STUDY_ID="STD-Siani-1987" TOTAL_1="1" TOTAL_2="1" WEIGHT="19.439124720814426"/>
<IV_DATA CI_END="1.5419477775830785" CI_START="-4.141947777583079" EFFECT_SIZE="-1.3" ESTIMABLE="YES" ESTIMATE="-1.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1199" SE="1.45" STUDY_ID="STD-Svetkey-1987" TOTAL_1="1" TOTAL_2="1" WEIGHT="25.400822060427537"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Potassium vs control (high quality trials)</NAME>
<CONT_OUTCOME CHI2="7.658953232381112" CI_END="5.712091767688524" CI_START="-19.928449969149266" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.1081791007303705" ESTIMABLE="YES" I2="86.94338547763782" I2_Q="0.0" ID="CMP-006.01" NO="1" P_CHI2="0.005649138688038624" P_Q="1.0" P_Z="0.2771698900970324" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="74.60177190908706" TOTALS="YES" TOTAL_1="72" TOTAL_2="66" UNITS="" WEIGHT="100.0" Z="1.0866989610501125">
<NAME>Systolic BP</NAME>
<GROUP_LABEL_1>Potassium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours potassium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-6.238670843682436" CI_START="-21.761329156317565" EFFECT_SIZE="-14.0" ESTIMABLE="YES" MEAN_1="131.8" MEAN_2="145.8" ORDER="1200" SD_1="12.7" SD_2="11.3" SE="3.959934579174892" STUDY_ID="STD-Siani-1987" TOTAL_1="18" TOTAL_2="19" WEIGHT="47.390680158247086"/>
<CONT_DATA CI_END="4.182838623000506" CI_START="-5.982838623000517" EFFECT_SIZE="-0.9000000000000057" ESTIMABLE="YES" MEAN_1="141.1" MEAN_2="142.0" ORDER="1201" SD_1="13.0" SD_2="13.0" SE="2.5933326648312387" STUDY_ID="STD-Svetkey-1987" TOTAL_1="54" TOTAL_2="47" WEIGHT="52.609319841752914"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.711720701986085" CI_END="3.4532824303221554" CI_START="-14.521208129038072" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.533962849357958" ESTIMABLE="YES" I2="87.03272539755675" I2_Q="0.0" ID="CMP-006.02" NO="2" P_CHI2="0.00548635603908143" P_Q="1.0" P_Z="0.22748518497621262" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="36.83224938824594" TOTALS="YES" TOTAL_1="72" TOTAL_2="66" UNITS="" WEIGHT="100.0" Z="1.206862340905234">
<NAME>Diastolic BP</NAME>
<GROUP_LABEL_1>Potassium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours potassium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.667569881188478" CI_START="-16.332430118811523" EFFECT_SIZE="-10.5" ESTIMABLE="YES" MEAN_1="82.0" MEAN_2="92.5" ORDER="1202" SD_1="8.9" SD_2="9.2" SE="2.9757843331902967" STUDY_ID="STD-Siani-1987" TOTAL_1="18" TOTAL_2="19" WEIGHT="46.02133531910816"/>
<CONT_DATA CI_END="1.5538911849900492" CI_START="-4.153891184990072" EFFECT_SIZE="-1.3000000000000114" ESTIMABLE="YES" MEAN_1="91.1" MEAN_2="92.4" ORDER="1203" SD_1="8.3" SD_2="6.3" SE="1.4560936871805756" STUDY_ID="STD-Svetkey-1987" TOTAL_1="54" TOTAL_2="47" WEIGHT="53.978664680891846"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Fig 1. Flow chart.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-02" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Fig 2. SBP funnel.</P>
<P>Standard error of treatment effect versus estimated treatment effect.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlsAAAGQCAMAAACu3FWpAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-03" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Fig 3. DBP funnel.</P>
<P>Standard error of treatment effect versus estimated treatment effect.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlsAAAGQCAMAAACu3FWpAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>